US20070260051A1 - siRNA targeting pituitary tumor-transforming 1 (PTTG1) - Google Patents
siRNA targeting pituitary tumor-transforming 1 (PTTG1) Download PDFInfo
- Publication number
- US20070260051A1 US20070260051A1 US11/811,925 US81192507A US2007260051A1 US 20070260051 A1 US20070260051 A1 US 20070260051A1 US 81192507 A US81192507 A US 81192507A US 2007260051 A1 US2007260051 A1 US 2007260051A1
- Authority
- US
- United States
- Prior art keywords
- sirna
- base
- sense strand
- sequence
- sirnas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Definitions
- the present invention relates to RNA interference (“RNAi”).
- RNAi RNA interference
- dsRNA double stranded RNA
- Double stranded RNA induced gene silencing can occur on at least three different levels: (i) transcription inactivation, which refers to RNA guided DNA or histone methylation; (ii) siRNA induced mRNA degradation; and (iii) mRNA induced transcriptional attenuation.
- RNAi RNA induced silencing
- siRNAs small inhibitory RNAs
- RNA binding Protein RDE-4 Interacts with RDE-1, DCR-1 and a DexH-box Helicase to Direct RNAi in C. elegans, Cell 109(7):861-71; Ketting et al. (2002) Dicer Functions in RNA Interference and in Synthesis of Small RNA Involved in Developmental Timing in C. elegans ; Martinez et al., Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi, Cell 110(5):563; Hutvagner & Zamore (2002) A microRNA in a multiple-turnover RNAi enzyme complex, Science 297:2056.
- Dicer Type III endonuclease known as Dicer.
- Dicer a Type III endonuclease known as Dicer.
- Dicer a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs. Bernstein, Caudy, Hammond, & Hannon (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature 409:363.
- RNA-induced silencing complex RISC
- one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition.
- Nykanen, Haley, & Zamore ATP requirements and small interfering RNA structure in the RNA interference pathway, Cell 107:309.
- one or more endonucleases within the RISC cleaves the target to induce silencing.
- Elbashir, Lendeckel, & Tuschl (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev. 15:188, FIG. 1.
- RNAi exhibits sequence specificity. Kisielow, M. et al. (2002) Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA, J. Biochem. 363:1-5. Thus, the RNAi machinery can specifically knock down one type of transcript, while not affecting closely related mRNA. These properties make siRNA a potentially valuable tool for inhibiting gene expression and studying gene function and drug target validation. Moreover, siRNAs are potentially useful as therapeutic agents against: (1) diseases that are caused by over-expression or misexpression of genes; and (2) diseases brought about by expression of genes that contain mutations.
- RNAi RNA-dependent gene silencing depends on a number of factors.
- One of the most contentious issues in RNAi is the question of the necessity of siRNA design, i.e., considering the sequence of the siRNA used.
- long dsRNA molecules are cleaved into siRNA by Dicer, thus generating a diverse population of duplexes that can potentially cover the entire transcript.
- siRNA design is not a crucial element of RNAi.
- others in the field have begun to explore the possibility that RNAi can be made more efficient by paying attention to the design of the siRNA.
- none of the reported methods have provided a satisfactory scheme for reliably selecting siRNA with acceptable levels of functionality. Accordingly, there is a need to develop rational criteria by which to select siRNA with an acceptable level of functionality, and to identify siRNA that have this improved level of functionality, as well as to identify siRNAs that are hyperfunctional.
- the present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.
- the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using non-target specific criteria.
- the present invention provides a method for selecting an siRNA, said method comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; and determining the relative functionality of the at least two siRNAs.
- the present invention also provides a method for selecting an siRNA wherein said selection criteria are embodied in a formula comprising: ( ⁇ 14)*G 13 ⁇ 13*A 1 ⁇ 12*U 7 ⁇ 11*U 2 ⁇ 10*A 11 ⁇ 10*U 4 ⁇ 10*C 3 ⁇ 10*C 5 ⁇ 10*C 6 ⁇ 9*A 10 ⁇ 9*U 9 ⁇ 9*C 18 ⁇ 8*G 10 ⁇ 7*U 1 ⁇ 7*U 16 ⁇ 7*C 17 ⁇ 7*C 19 +7*U 17 +8*A 2 +8*A 4 +8*A 5 +8*C 4 +9*G 8 +10*A 7 +10*U 18 +11*A 19 +11*C 9 +15*G 1 +18*A 3 +19*U 10 ⁇ Tm ⁇ 3*(GC total ) ⁇ 6*(GC 15-19 ) ⁇ 30*X; or Formula VIII: ( ⁇ 8)*A1+( ⁇ 1)*A2+(12)*A3+
- the invention provides a method for developing an algorithm for selecting siRNA, said method comprising: (a) selecting a set of siRNA; (b) measuring gene silencing ability of each siRNA from said set; (c) determining relative functionality of each siRNA; (d) determining improved functionality by the presence or absence of at least one variable selected from the group consisting of the presence or absence of a particular nucleotide at a particular position, the total number of As and Us in positions 15-19, the number of times that the same nucleotide repeats within a given sequence, and the total number of Gs and Cs; and (e) developing an algorithm using the information of step (d).
- the present invention provides a kit, wherein said kit is comprised of at least two siRNAs, wherein said at least two siRNAs comprise a first optimized siRNA and a second optimized siRNA, wherein said first optimized siRNA and said second optimized siRNA are optimized according a formula comprising Formula X.
- the present invention also provides a method for identifying a hyperfunctional siRNA, comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; determining the relative functionality of the at least two siRNAs and assigning each of the at least two siRNAs a functionality score; and selecting siRNAs from the at least two siRNAs that have a functionality score that reflects greater than 80 percent silencing at a concentration in the picomolar range, wherein said greater than 80 percent silencing endures for greater than 120 hours.
- the present invention provides a hyperfunctional siRNA that is capable of silencing Bcl2.
- the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence.
- the method comprises:
- step (e) developing an algorithm using the information of step (d).
- the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.
- the present invention provides rationally designed siRNAs identified using the formulas above.
- the present invention is directed to hyperfunctional siRNA.
- siRNAs that target pituitary tumor-transforming 1 are provided.
- the siRNAs are rationally designed.
- the siRNAs are functional or hyperfunctional.
- an siRNA that targets PTTG1 is provided, wherein the siRNA is selected from the group consisting of various siRNA sequences targeting PTTG1 that are disclosed herein.
- the siRNA sequence is selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- siRNA comprising a sense region and an antisense region
- said sense region and said antisense region are at least 90% complementary
- said sense region and said antisense region together form a duplex region comprising 18-30 base pairs
- said sense region comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of siRNA sequences targeting PTTG1 that are disclosed herein.
- the siRNA sequence is selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- an siRNA comprising a sense region and an antisense region
- said sense region and said antisense region are at least 90% complementary
- said sense region and said antisense region together form a duplex region comprising 18-30 base pairs
- said sense region comprises a sequence that is identical to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- the duplex region is 19-30 base pairs
- the sense region comprises a sequence that is identical to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- a pool of at least two siRNAs comprises a first siRNA and a second siRNA, said first siRNA comprising a duplex region of length 18-30 base pairs that has a first sense region that is at least 90% similar to 18 bases of a first sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, and said second siRNA comprises a duplex region of length 18-30 base pairs that has a second sense region that is at least 90% similar to 18 bases of a second sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, wherein said first sense region and said second sense region are not identical.
- the first sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498
- said second sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498
- the duplex of said first siRNA is 19-30 base pairs
- said first sense region comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498
- said duplex of said second siRNA is 19-30 base pairs and comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- the duplex of said first siRNA is 19-30 base pairs and said first sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, and said duplex of said second siRNA is 19-30 base pairs and said second region comprises a sequence that is identical to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- FIG. 1 shows a model for siRNA-RISC interactions.
- RISC has the ability to interact with either end of the siRNA or miRNA molecule. Following binding, the duplex is unwound, and the relevant target is identified, cleaved, and released.
- FIG. 2 is a representation of the functionality of two hundred and seventy siRNA duplexes that were generated to target human cyclophilin, human diazepam-binding inhibitor (DB), and firefly luciferase.
- FIG. 3 a is a representation of the silencing effect of 30 siRNAs in three different cells lines, HEK293, DU145, and Hela.
- FIG. 3 b shows the frequency of different functional groups (>95% silencing (black), >80% silencing (gray), >50% silencing (dark gray), and ⁇ 50% silencing (white)) based on GC content. In cases where a given bar is absent from a particular GC percentage, no siRNA were identified for that particular group.
- FIG. 3 c shows the frequency of different functional groups based on melting temperature (Tm).
- FIGS. 4A-4E are representations of a statistical analysis that revealed correlations between silencing and five sequence-related properties of siRNA: (A) an A at position 19 of the sense strand, (B) an A at position 3 of the sense strand, (C) a U at position 10 of the sense strand, (D) a base other than G at position 13 of the sense strand, and (E) a base other than C at position 19 of the sense strand. All variables were correlated with siRNA silencing of firefly luciferase and human cyclophilin. siRNAs satisfying the criterion are grouped on the left (Selected) while those that do not, are grouped on the right (Eliminated). Y-axis is “% Silencing of Control.” Each position on the X-axis represents a unique siRNA.
- FIGS. 5A and 5B are representations of firefly luciferase and cyclophilin siRNA panels sorted according to functionality and predicted values using Formula VIII.
- the siRNA found within the circle represent those that have Formula VIII values (SMARTSCORESTM, or siRNA rank) above zero. siRNA outside the indicated area have calculated Formula VIII values that are below zero.
- Y-axis is “Expression (% Control).” Each position on the X-axis represents a unique siRNA.
- FIG. 6A is a representation of the average internal stability profile (AISP) derived from 270 siRNAs taken from three separate genes (cyclophilin B, DBI and firefly luciferase). Graphs represent AISP values of highly functional, functional, and non-functional siRNA.
- FIG. 6B is a comparison between the AISP of naturally derived GFP siRNA (filled squares) and the AISP of siRNA from cyclophilin B, DBI, and luciferase having >90% silencing properties (no fill) for the antisense strand. “DG” is the symbol for ⁇ G, free energy.
- FIG. 7 is a histogram showing the differences in duplex functionality upon introduction of base pair mismatches.
- the X-axis shows the mismatch introduced in the siRNA and the position it is introduced (e.g., 8C>A reveals that position 8 (which normally has a C) has been changed to an A).
- the Y-axis is “% Silencing (Normalized to Control).”
- the samples on the X-axis represent siRNAs at 100 nM and are, reading from left to right: 1A to C, 1A to G, 1A to U; 2A to C, 2A to G, 2A to U; 3A to C, 3A to G, 3A to U; 4G to A, 4G to C; 4G to U; 5U to A, 5U to C, 5U to G; 6U to A, 6U to C, 6U to G; 7G to A, 7G to C, 7G to U; 8C to A, 8C to G, 8C to U; 9G to A, 9G to C, 9G to U; 10C to A, 10C to G, 10C to U; 11G to A, 11G to C, 11G to U; 12G to A, 12G to C, 12G to U; 13A to C, 13A to G, 13A to U; 14G to A, 14G to C,
- FIG. 8A is histogram that shows the effects of 5′sense and antisense strand modification with 2′-O-methylation on functionality.
- FIG. 8B is an expression profile showing a comparison of sense strand off-target effects for IGF1R-3 and 2′-O-methyl IGF1R-3. Sense strand off-targets (lower box) are not induced when the 5′ end of the sense strand is modified with 2′-O-methyl groups (top box).
- FIG. 9 shows a graph of SMARTSCORESTM, or siRNA rank, versus RNAi silencing values for more than 360 siRNA directed against 30 different genes.
- SiRNA to the right of the vertical bar represent those siRNA that have desirable SMARTSCORESTM, or siRNA rank.
- FIGS. 10 A-E compare the RNAi of five different genes (SEAP, DBI, PLK, Firefly Luciferase, and Renilla Luciferase) by varying numbers of randomly selected siRNA and four rationally designed (SMART-selected) siRNA chosen using the algorithm described in Formula VIII.
- RNAi induced by a pool of the four SMART-selected siRNA is reported at two different concentrations (100 and 400 nM).
- 10 F is a comparison between a pool of randomly selected EGFR siRNA (Pool 1) and a pool of SMART-selected EGFR siRNA (Pool 2). Pool 1, S1-S4 and Pool 2 S1-S4 represent the individual members that made up each respective pool. Note that numbers for random siRNAs represent the position of the 5′ end of the sense strand of the duplex.
- the Y-axis represents the % expression of the control(s).
- the X-axis is the percent expression of the control.
- FIG. 11 shows the Western blot results from cells treated with siRNA directed against twelve different genes involved in the clathrin-dependent endocytosis pathway (CHC, DynII, CALM, CLCa, CLCb, Eps15, Eps15R, Rab5a, Rab5b, Rab5c, ⁇ 2 subunit of AP-2 and EEA.1).
- siRNA were selected using Formula VIII.
- FIG. 12 is a representation of the gene silencing capabilities of rationally-selected siRNA directed against ten different genes (human and mouse cyclophilin, C-myc, human lamin A/C, QB (ubiquinol-cytochrome c reductase core protein I), MEK1 and MEK2, ATE1 (arginyl-tRNA protein transferase), GAPDH, and Eg5).
- the Y-axis is the percent expression of the control. Numbers 1, 2, 3 and 4 represent individual rationally selected siRNA. “Pool” represents a mixture of the four individual siRNA.
- FIG. 13 is the sequence of the top ten Bcl2 siRNAs as determined by Formula VIII. Sequences are listed 5′ to 3′.
- FIG. 14 is the knockdown by the top ten Bcl2 siRNAs at 100 nM concentrations.
- the Y-axis represents the amount of expression relative to the non-specific (ns) and transfection mixture control.
- FIG. 15 represents a functional walk where siRNA beginning on every other base pair of a region of the luciferase gene are tested for the ability to silence the luciferase gene.
- the Y-axis represents the percent expression relative to a control.
- the X-axis represents the position of each individual siRNA. Reading from left to right across the X-axis, the position designations are 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.
- FIGS. 16A and 16B are histograms demonstrating the inhibition of target gene expression by pools of 2 ( 16 A) and 3 ( 16 B) siRNA duplexes taken from the walk described in FIG. 15 .
- the Y-axis in each represents the percent expression relative to control.
- the X-axis in each represents the position of the first siRNA in paired pools, or trios of siRNAs. For instance, the first paired pool contains siRNAs 1 and 3.
- the second paired pool contains siRNAs 3 and 5.
- Pool 3 (of paired pools) contains siRNAs 5 and 7, and so on.
- the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.
- FIGS. 17A and 17B are histograms demonstrating the inhibition of target gene expression by pools of 4 ( 17 A) and 5 ( 17 B) siRNA duplexes.
- the Y-axis in each represents the percent expression relative to control.
- the X-axis in each represents the position of the first siRNA in each pool.
- the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.
- FIGS. 18A and 18B are histograms demonstrating the inhibition of target gene expression by siRNAs that are ten ( 18 A) and twenty ( 18 B) base pairs base pairs apart.
- the Y-axis represents the percent expression relative to a control.
- the X-axis represents the position of the first siRNA in each pool.
- the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.
- FIG. 19 shows that pools of siRNAs (dark gray bar) work as well (or better) than the best siRNA in the pool (light gray bar).
- the Y-axis represents the percent expression relative to a control.
- the X-axis represents the position of the first siRNA in each pool.
- the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid.
- FIG. 20 shows that the combination of several semifunctional siRNAs (dark gray) result in a significant improvement of gene expression inhibition over individual (semi-functional; light gray) siRNA.
- the Y-axis represents the percent expression relative to a control.
- FIGS. 21A, 21B and 21 C show both pools (Library, Lib) and individual siRNAs in inhibition of gene expression of Beta-Galactosidase, Renilla Luciferase and SEAP (alkaline phosphatase).
- Numbers on the X-axis indicate the position of the 5′-most nucleotide of the sense strand of the duplex.
- the Y-axis represents the percent expression of each gene relative to a control.
- Libraries contain 19 nucleotide long siRNAs (not including overhangs) that begin at the following nucleotides: SEAP: Lib 1: 206, 766, 812, 923, Lib 2: 1117, 1280, 1300, 1487, Lib 3: 206, 766, 812, 923, 1117, 1280, 1300, 1487, Lib 4: 206, 812, 1117, 1300, Lib 5: 766, 923, 1280, 1487, Lib 6: 206, 1487; Bgal: Lib 1: 979, 1339, 2029, 2590, Lib 2: 1087, 1783, 2399, 3257, Lib 3: 979, 1783, 2590, 3257, Lib 4: 979, 1087, 1339, 1783, 2029, 2399, 2590, 3257, Lib 5: 979, 1087, 1339, 1783, Lib 6: 2029, 2399, 2590, 3257; Renilla : Lib 1
- FIG. 22 shows the results of an EGFR and TfnR internalization assay when single gene knockdowns are performed.
- the Y-axis represents percent internalization relative to control.
- FIG. 23 shows the results of an EGFR and TfnR internalization assay when multiple genes are knocked down (e.g., Rab5a, b, c).
- the Y-axis represents the percent internalization relative to control.
- FIG. 24 shows the simultaneous knockdown of four different genes.
- siRNAs directed against G6PD, GAPDH, PLK, and UQC were simultaneously introduced into cells. Twenty-four hours later, cultures were harvested and assayed for mRNA target levels for each of the four genes. A comparison is made between cells transfected with individual siRNAs vs. a pool of siRNAs directed against all four genes.
- FIG. 25 shows the functionality of ten siRNAs at 0.3 nM concentrations.
- Complementary refers to the ability of polynucleotides to form base pairs with one another. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes.
- Watson-Crick manner e.g., A to T, A to U, C to G
- uracil rather than thymine is the base that is considered to be complementary to adenosine.
- a U is denoted in the context of the present invention, the ability to substitute a T is implied, unless otherwise stated.
- Perfect complementarity or 100% complementarity refers to the situation in which each nucleotide unit of one polynucleotide strand can hydrogen bond with a nucleotide unit of a second polynucleotide strand.
- Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands can hydrogen bond with each other. For example, for two 20-mers, if only two base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 10% complementarity. In the same example, if 18 base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 90% complementarity.
- deoxynucleotide refers to a nucleotide or polynucleotide lacking a hydroxyl group (OH group) at the 2′ and/or 3′ position of a sugar moiety. Instead, it has a hydrogen bonded to the 2′ and/or 3′ carbon.
- deoxynucleotide refers to the lack of an OH group at the 2′ position of the sugar moiety, having instead a hydrogen bonded directly to the 2′ carbon.
- deoxyribonucleotide and “DNA” refer to a nucleotide or polynucleotide comprising at least one sugar moiety that has an H, rather than an OH, at its 2′ and/or 3′position.
- duplex region refers to the region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a stabilized duplex between polynucleotide strands that are complementary or substantially complementary.
- a polynucleotide strand having 21 nucleotide units can base pair with another polynucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex region” has 19 base pairs.
- the remaining bases may, for example, exist as 5′ and 3′ overhangs.
- 100% complementarity is not required; substantial complementarity is allowable within a duplex region.
- Substantial complementarity refers to 79% or greater complementarity. For example, a mismatch in a duplex region consisting of 19 base pairs results in 94.7% complementarity, rendering the duplex region substantially complementary.
- filter refers to one or more procedures that are performed on sequences that are identified by the algorithm.
- filtering includes in silico procedures where sequences identified by the algorithm can be screened to identify duplexes carrying desirable or undesirable motifs. Sequences carrying such motifs can be selected for, or selected against, to obtain a final set with the preferred properties.
- filtering includes wet lab experiments. For instance, sequences identified by one or more versions of the algorithm can be screened using any one of a number of procedures to identify duplexes that have hyperfunctional traits (e.g., they exhibit a high degree of silencing at subnanomolar concentrations and/or exhibit high degrees of silencing longevity).
- gene silencing refers to a process by which the expression of a specific gene product is lessened or attenuated. Gene silencing can take place by a variety of pathways. Unless specified otherwise, as used herein, gene silencing refers to decreases in gene product expression that results from RNA interference (RNAi), a defined, though partially characterized pathway whereby small inhibitory RNA (siRNA) act in concert with host proteins (e.g., the RNA induced silencing complex, RISC) to degrade messenger RNA (mRNA) in a sequence-dependent fashion.
- RNAi RNA interference
- host proteins e.g., the RNA induced silencing complex, RISC
- the level of gene silencing can be measured by a variety of means, including, but not limited to, measurement of transcript levels by Northern Blot Analysis, B-DNA techniques, transcription-sensitive reporter constructs, expression profiling (e.g., DNA chips), and related technologies.
- the level of silencing can be measured by assessing the level of the protein encoded by a specific gene. This can be accomplished by performing a number of studies including Western Analysis, measuring the levels of expression of a reporter protein that has e.g., fluorescent properties (e.g., GFP) or enzymatic activity (e.g., alkaline phosphatases), or several other procedures.
- fluorescent properties e.g., GFP
- enzymatic activity e.g., alkaline phosphatases
- microRNA refers to microRNA.
- nucleotide refers to a ribonucleotide or a deoxyribonucleotide or modified form thereof, as well as an analog thereof.
- Nucleotides include species that comprise purines, e.g., adenine, hypoxanthine, guanine, and their derivatives and analogs, as well as pyrimidines, e.g., cytosine, uracil, thymine, and their derivatives and analogs.
- Nucleotide analogs include nucleotides having modifications in the chemical structure of the base, sugar and/or phosphate, including, but not limited to, 5-position pyrimidine modifications, 8-position purine modifications, modifications at cytosine exocyclic amines, and substitution of 5-bromo-uracil; and 2′-position sugar modifications, including but not limited to, sugar-modified ribonucleotides in which the 2′-OH is replaced by a group such as an H, OR, R, halo, SH, SR, NH 2 , NHR, NR 2 , or CN, wherein R is an alkyl moiety.
- Nucleotide analogs are also meant to include nucleotides with bases such as inosine, queuosine, xanthine, sugars such as 2′-methyl ribose, non-natural phosphodiester linkages such as methylphosphonates, phosphorothioates and peptides.
- Modified bases refer to nucleotide bases such as, for example, adenine, guanine, cytosine, thymine, uracil, xanthine, inosine, and queuosine that have been modified by the replacement or addition of one or more atoms or groups.
- nucleotide bases such as, for example, adenine, guanine, cytosine, thymine, uracil, xanthine, inosine, and queuosine that have been modified by the replacement or addition of one or more atoms or groups.
- Some examples of types of modifications that can comprise nucleotides that are modified with respect to the base moieties include but are not limited to, alkylated, halogenated, thiolated, aminated, amidated, or acetylated bases, individually or in combination.
- More specific examples include, for example, 5-propynyluridine, 5-propynylcytidine, 6-methyladenine, 6-methylguanine, N,N,-dimethyladenine, 2-propyladenine, 2-propylguanine, 2-aminoadenine, 1-methylinosine, 3-methyluridine, 5-methylcytidine, 5-methyluridine and other nucleotides having a modification at the 5 position, 5-(2-amino)propyl uridine, 5-halocytidine, 5-halouridine, 4-acetylcytidine, 1-methyladenosine, 2-methyladenosine, 3-methylcytidine, 6-methyluridine, 2-methylguanosine, 7-methylguanosine, 2,2-dimethylguanosine, 5-methylaminoethyluridine, 5-methyloxyuridine, deazanucleotides such as 7-deaza-adenosine, 6-azouridine, 6-azocytidine, 6-azo
- Modified nucleotides also include those nucleotides that are modified with respect to the sugar moiety, as well as nucleotides having sugars or analogs thereof that are not ribosyl.
- the sugar moieties may be, or be based on, mannoses, arabinoses, glucopyranoses, galactopyranoses, 4′-thioribose, and other sugars, heterocycles, or carbocycles.
- nucleotide is also meant to include what are known in the art as universal bases.
- universal bases include but are not limited to 3-nitropyrrole, 5-nitroindole, or nebularine.
- nucleotide is also meant to include the N3′ to P5′ phosphoramidate, resulting from the substitution of a ribosyl 3′ oxygen with an amine group.
- nucleotide also includes those species that have a detectable label, such as for example a radioactive or fluorescent moiety, or mass label attached to the nucleotide.
- off-target silencing and “off-target interference” are defined as degradation of mRNA other than the intended target mRNA due to overlapping and/or partial homology with secondary mRNA messages.
- polynucleotide refers to polymers of nucleotides, and includes but is not limited to DNA, RNA, DNA/RNA hybrids including polynucleotide chains of regularly and/or irregularly alternating deoxyribosyl moieties and ribosyl moieties (i.e., wherein alternate nucleotide units have an —OH, then and —H, then an —OH, then an —H, and so on at the 2′ position of a sugar moiety), and modifications of these kinds of polynucleotides, wherein the attachment of various entities or moieties to the nucleotide units at any position are included.
- polyribonucleotide refers to a polynucleotide comprising two or more modified or unmodified ribonucleotides and/or their analogs.
- polyribonucleotide is used interchangeably with the term “oligoribonucleotide.”
- ribonucleotide and the phrase “ribonucleic acid” (RNA), refer to a modified or unmodified nucleotide or polynucleotide comprising at least one ribonucleotide unit.
- a ribonucleotide unit comprises an hydroxyl group attached to the 2′ position of a ribosyl moiety that has a nitrogenous base attached in N-glycosidic linkage at the 1′ position of a ribosyl moiety, and a moiety that either allows for linkage to another nucleotide or precludes linkage.
- siRNA refers to small inhibitory RNA duplexes that induce the RNA interference (RNAi) pathway. These molecules can vary in length (generally 18-30 base pairs) and contain varying degrees of complementarity to their target mRNA in the antisense strand. Some, but not all, siRNA have unpaired overhanging bases on the 5′ or 3′ end of the sense strand and/or the antisense strand.
- siRNA includes duplexes of two separate strands, as well as single strands that can form hairpin structures comprising a duplex region.
- siRNA may be divided into five (5) groups (non-functional, semi-functional, functional, highly functional, and hyper-functional) based on the level or degree of silencing that they induce in cultured cell lines. As used herein, these definitions are based on a set of conditions where the siRNA is transfected into said cell line at a concentration of 100 nM and the level of silencing is tested at a time of roughly 24 hours after transfection, and not exceeding 72 hours after transfection. In this context, “non-functional siRNA” are defined as those siRNA that induce less than 50% ( ⁇ 50%) target silencing. “Semi-functional siRNA” induce 50-79% target silencing. “Functional siRNA” are molecules that induce 80-95% gene silencing.
- “Highly-functional siRNA” are molecules that induce greater than 95% gene silencing. “Hyperfunctional siRNA” are a special class of molecules. For purposes of this document, hyperfunctional siRNA are defined as those molecules that: (1) induce greater than 95% silencing of a specific target when they are transfected at subnanomolar concentrations (i.e., less than one nanomolar); and/or (2) induce functional (or better) levels of silencing for greater than 96 hours. These relative functionalities (though not intended to be absolutes) may be used to compare siRNAs to a particular target for applications such as functional genomics, target identification and therapeutics.
- SMARTSCORETM or “siRNA rank” refers to a number determined by applying any of the formulas to a given siRNA sequence.
- SMART-selected or “rationally selected” or “rational selection” refers to siRNA that have been selected on the basis of their SMARTSCORESTM, or siRNA ranking.
- substantially similar refers to a similarity of at least 90% with respect to the identity of the bases of the sequence.
- target is used in a variety of different forms throughout this document and is defined by the context in which it is used.
- Target mRNA refers to a messenger RNA to which a given siRNA can be directed against.
- Target sequence and “target site” refer to a sequence within the mRNA to which the sense strand of an siRNA shows varying degrees of homology and the antisense strand exhibits varying degrees of complementarity.
- siRNA target can refer to the gene, mRNA, or protein against which an siRNA is directed.
- target silencing can refer to the state of a gene, or the corresponding mRNA or protein.
- transfection refers to a process by which agents are introduced into a cell.
- the list of agents that can be transfected is large and includes, but is not limited to, siRNA, sense and/or anti-sense sequences, DNA encoding one or more genes and organized into an expression plasmid, proteins, protein fragments, and more.
- methods for transfecting agents into a cell including, but not limited to, electroporation, calcium phosphate-based transfections, DEAE-dextran-based transfections, lipid-based transfections, molecular conjugate-based transfections (e.g., polylysine-DNA conjugates), microinjection and others.
- the present invention is directed to improving the efficiency of gene silencing by siRNA. Through the inclusion of multiple siRNA sequences that are targeted to a particular gene and/or selecting an siRNA sequence based on certain defined criteria, improved efficiency may be achieved.
- the present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.
- the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using non-target specific criteria.
- Each of the at least two siRNA duplexes of the kit complementary to a portion of the sequence of one or more target mRNAs is preferably selected using Formula X.
- the present invention provides a method for selecting an siRNA, said method comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; and determining the relative functionality of the at least two siRNAs.
- the present invention also provides a method wherein said selection criteria are embodied in a formula comprising: ( ⁇ 14)*G 13 ⁇ 13*A 1 ⁇ 12*U 7 ⁇ 11*U 2 ⁇ 10*A 11 ⁇ 10*U 4 ⁇ 10*C 3 ⁇ 10*C 5 ⁇ 10*C 6 ⁇ 9*A 10 ⁇ 9*U 9 ⁇ 9*C 18 ⁇ 8*G 10 ⁇ 7*U 1 ⁇ 7*U 16 ⁇ 7*C 17 ⁇ 7*C 19 +7*U 17 +8*A 2 +8*A 4 +8*A 5 +8*C 4 +9*G 8 +10*A 7 +10*U 18 +11*A 19 +11*C 9 +15*G 1 +18*A 3 +19*U 10 ⁇ Tm ⁇ 3*(GC total ) ⁇ 6*(GC 15-19 ) ⁇ 30*X; or Formula VIII: ( ⁇ 8)*A1+( ⁇ 1)*A2+(12)*A3+(7)*A4+(18)
- a 1 1 if A is the base at position 1 of the sense strand, otherwise its value is 0;
- G 1 1 if G is the base at position 1 on the sense strand, otherwise its value is 0;
- U 1 1 if U is the base at position 1 on the sense strand, otherwise its value is 0;
- GC 15-19 the number of G and C bases within positions 15-19 of the sense strand, or within positions 15-18 if the sense strand is only 18 base pairs in length;
- GC total the number of G and C bases in the sense strand
- Tm 100 if the siRNA oligo has the internal repeat longer then 4 base pairs, otherwise its value is 0;
- X the number of times that the same nucleotide repeats four or more times in a row.
- any of the methods of selecting siRNA in accordance with the invention can further comprise comparing the internal stability profiles of the siRNAs to be selected, and selecting those siRNAs with the most favorable internal stability profiles. Any of the methods of selecting siRNA can further comprise selecting either for or against sequences that contain motifs that induce cellular stress. Such motifs include, for example, toxicity motifs. Any of the methods of selecting siRNA can further comprise either selecting for or selecting against sequences that comprise stability motifs.
- the present invention provides a method of gene silencing, comprising introducing into a cell at least one siRNA selected according to any of the methods of the present invention.
- the siRNA can be introduced by allowing passive uptake of siRNA, or through the use of a vector.
- the invention provides a method for developing an algorithm for selecting siRNA, said method comprising: (a) selecting a set of siRNA; (b) measuring gene silencing ability of each siRNA from said set; (c) determining relative functionality of each siRNA; (d) determining improved functionality by the presence or absence of at least one variable selected from the group consisting of the presence or absence of a particular nucleotide at a particular position, the total number of As and Us in positions 15-19, the number of times that the same nucleotide repeats within a given sequence, and the total number of Gs and Cs; and (e) developing an algorithm using the information of step (d).
- the invention provides a method for selecting an siRNA with improved functionality, comprising using the above-mentioned algorithm to identify an siRNA of improved functionality.
- the present invention provides a kit, wherein said kit is comprised of at least two siRNAs, wherein said at least two siRNAs comprise a first optimized siRNA and a second optimized siRNA, wherein said first optimized siRNA and said second optimized siRNA are optimized according a formula comprising Formula X.
- the present invention provides a method for identifying a hyperfunctional siRNA, comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; determining the relative functionality of the at least two siRNAs and assigning each of the at least two siRNAs a functionality score; and selecting siRNAs from the at least two siRNAs that have a functionality score that reflects greater than 80 percent silencing at a concentration in the picomolar range, wherein said greater than 80 percent silencing endures for greater than 120 hours.
- the invention provides kits and/or methods wherein the siRNA are comprised of two separate polynucleotide strands; wherein the siRNA are comprised of a single contiguous molecule such as, for example, a unimolecular siRNA (comprising, for example, either a nucleotide or non-nucleotide loop); wherein the siRNA are expressed from one or more vectors; and wherein two or more genes are silenced by a single administration of siRNA.
- a unimolecular siRNA comprising, for example, either a nucleotide or non-nucleotide loop
- the present invention provides a hyperfunctional siRNA that is capable of silencing Bcl2.
- the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence.
- the method comprises:
- step (e) developing an algorithm using the information of step (d).
- the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.
- the present invention provides rationally designed siRNAs identified using the formulas above.
- the present invention is directed to hyperfunctional siRNA.
- the methods disclosed herein can be used in conjunction with comparing internal stability profiles of selected siRNAs, and designing an siRNA with a desirable internal stability profile; and/or in conjunction with a selection either for or against sequences that contain motifs that induce cellular stress, for example, cellular toxicity.
- siRNA(s) can be introduced into the cell by any method known in the art, including passive uptake or through the use of one or more vectors.
- any of the methods and kits disclosed herein can employ either unimolecular siRNAs, siRNAs comprised of two separate polynucleotide strands, or combinations thereof. Any of the methods disclosed herein can be used in gene silencing, where two or more genes are silenced by a single administration of siRNA(s).
- the siRNA(s) can be directed against two or more target genes, and administered in a single dose or single transfection, as the case may be.
- the present invention provides a method for improving the effectiveness of gene silencing for use to silence a particular gene through the selection of an optimal siRNA.
- An siRNA selected according to this method may be used individually, or in conjunction with the first embodiment, i.e., with one or more other siRNAs, each of which may or may not be selected by this criteria in order to maximize their efficiency.
- an siRNA is selected for a given gene by using a rational design. That said, rational design can be described in a variety of ways. Rational design is, in simplest terms, the application of a proven set of criteria that enhance the probability of identifying a functional or hyperfunctional siRNA. In one method, rationally designed siRNA can be identified by maximizing one or more of the following criteria:
- a low GC content preferably between about 30-52%.
- a Tm which refers to the character of the internal repeat that results in inter- or intramolecular structures for one strand of the duplex, that is preferably not stable at greater than 50° C., more preferably not stable at greater than 37° C., even more preferably not stable at greater than 30° C. and most preferably not stable at greater than 20° C.
- a C base at position 10 of the sense strand makes a minor contribution to duplex functionality.
- the absence of a C at position 3 of the sense strand is very important. Accordingly, preferably an siRNA will satisfy as many of the aforementioned criteria as possible.
- GC content as well as a high number of AU in positions 15-19 of the sense strand, may be important for easement of the unwinding of double stranded siRNA duplex.
- Duplex unwinding has been shown to be crucial for siRNA functionality in vivo.
- the internal structure is measured in terms of the melting temperature of the single strand of siRNA, which is the temperature at which 50% of the molecules will become denatured.
- the positions refer to sequence positions on the sense strand, which is the strand that is identical to the mRNA.
- At least criteria 1 and 8 are satisfied. In another preferred embodiment, at least criteria 7 and 8 are satisfied. In still another preferred embodiment, at least criteria 1, 8 and 9 are satisfied.
- the base pair that is not present is the base pair that is located at the 3′ of the sense strand.
- additional bases are added at the 5′ end of the sense chain and occupy positions ⁇ 1 to ⁇ 11.
- SEQ. ID NO. 0001 NNANANNNNUCNAANNNNA and SEQ. ID NO. 0028 GUCNNANANNNNUCNAANNNNA both would have A at position 3, A at position 5, U at position 10, C at position 11, A and position 13, A and position 14 and A at position 19.
- SEQ. ID NO. 0028 would also have C at position ⁇ 1, U at position ⁇ 2 and G at position ⁇ 3.
- N is any base, A, C, G, or U:
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PTTG1.
Description
- This application is a continuation-in-part of U.S. Ser. No. 10/714,333, filed Nov. 14, 2003, which claims the benefit of U.S. Provisional Application No. 60/426,137, filed Nov. 14, 2002, and also claims the benefit of U.S. Provisional Application No. 60/502,050, filed Sep. 10, 2003; this application is also a continuation-in-part of U.S. Ser. No. 10/940,892, filed Sep. 14, 2004, which is a continuation of PCT Application No. PCT/US 04/14885, international filing date May 12, 2004. The disclosures of the priority applications, including the sequence listings and tables submitted in electronic form in lieu of paper, are incorporated by reference into the instant specification.
- The sequence listing for this application has been submitted in accordance with 37 CFR § 1.52(e) and 37 CFR § 1.821 on CD-ROM in lieu of paper on a disk containing the sequence listing file entitled “DHARMA—2100-US45_CRF.txt” created May 30, 2007, 88 kb. Applicants hereby incorporate by reference the sequence listing provided on CD-ROM in lieu of paper into the instant specification.
- The present invention relates to RNA interference (“RNAi”).
- Relatively recently, researchers observed that double stranded RNA (“dsRNA”) could be used to inhibit protein expression. This ability to silence a gene has broad potential for treating human diseases, and many researchers and commercial entities are currently investing considerable resources in developing therapies based on this technology.
- Double stranded RNA induced gene silencing can occur on at least three different levels: (i) transcription inactivation, which refers to RNA guided DNA or histone methylation; (ii) siRNA induced mRNA degradation; and (iii) mRNA induced transcriptional attenuation.
- It is generally considered that the major mechanism of RNA induced silencing (RNA interference, or RNAi) in mammalian cells is mRNA degradation. Initial attempts to use RNAi in mammalian cells focused on the use of long strands of dsRNA. However, these attempts to induce RNAi met with limited success, due in part to the induction of the interferon response, which results in a general, as opposed to a target-specific, inhibition of protein synthesis. Thus, long dsRNA is not a viable option for RNAi in mammalian systems.
- More recently it has been shown that when short (18-30 bp) RNA duplexes are introduced into mammalian cells in culture, sequence-specific inhibition of target mRNA can be realized without inducing an interferon response. Certain of these short dsRNAs, referred to as small inhibitory RNAs (“siRNAs”), can act catalytically at sub-molar concentrations to cleave greater than 95% of the target mRNA in the cell. A description of the mechanisms for siRNA activity, as well as some of its applications are described in Provost et al. (2002) Ribonuclease Activity and RNA Binding of Recombinant Human Dicer, EMBO J. 21(21): 5864-5874; Tabara et al. (2002) The dsRNA Binding Protein RDE-4 Interacts with RDE-1, DCR-1 and a DexH-box Helicase to Direct RNAi in C. elegans, Cell 109(7):861-71; Ketting et al. (2002) Dicer Functions in RNA Interference and in Synthesis of Small RNA Involved in Developmental Timing in C. elegans; Martinez et al., Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi, Cell 110(5):563; Hutvagner & Zamore (2002) A microRNA in a multiple-turnover RNAi enzyme complex, Science 297:2056.
- From a mechanistic perspective, introduction of long double stranded RNA into plants and invertebrate cells is broken down into siRNA by a Type III endonuclease known as Dicer. Sharp, RNA interference—2001, Genes Dev. 2001, 15:485. Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two
base 3′ overhangs. Bernstein, Caudy, Hammond, & Hannon (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature 409:363. The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition. Nykanen, Haley, & Zamore (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway, Cell 107:309. Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleaves the target to induce silencing. Elbashir, Lendeckel, & Tuschl (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev. 15:188, FIG. 1. - The interference effect can be long lasting and may be detectable after many cell divisions. Moreover, RNAi exhibits sequence specificity. Kisielow, M. et al. (2002) Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA, J. Biochem. 363:1-5. Thus, the RNAi machinery can specifically knock down one type of transcript, while not affecting closely related mRNA. These properties make siRNA a potentially valuable tool for inhibiting gene expression and studying gene function and drug target validation. Moreover, siRNAs are potentially useful as therapeutic agents against: (1) diseases that are caused by over-expression or misexpression of genes; and (2) diseases brought about by expression of genes that contain mutations.
- Successful siRNA-dependent gene silencing depends on a number of factors. One of the most contentious issues in RNAi is the question of the necessity of siRNA design, i.e., considering the sequence of the siRNA used. Early work in C. elegans and plants circumvented the issue of design by introducing long dsRNA (see, for instance, Fire, A. et al. (1998) Nature 391:806-811). In this primitive organism, long dsRNA molecules are cleaved into siRNA by Dicer, thus generating a diverse population of duplexes that can potentially cover the entire transcript. While some fraction of these molecules are non-functional (i.e., induce little or no silencing) one or more have the potential to be highly functional, thereby silencing the gene of interest and alleviating the need for siRNA design. Unfortunately, due to the interferon response, this same approach is unavailable for mammalian systems. While this effect can be circumvented by bypassing the Dicer cleavage step and directly introducing siRNA, this tactic carries with it the risk that the chosen siRNA sequence may be non-functional or semi-functional.
- A number of researches have expressed the view that siRNA design is not a crucial element of RNAi. On the other hand, others in the field have begun to explore the possibility that RNAi can be made more efficient by paying attention to the design of the siRNA. Unfortunately, none of the reported methods have provided a satisfactory scheme for reliably selecting siRNA with acceptable levels of functionality. Accordingly, there is a need to develop rational criteria by which to select siRNA with an acceptable level of functionality, and to identify siRNA that have this improved level of functionality, as well as to identify siRNAs that are hyperfunctional.
- The present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.
- According to a first embodiment, the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using non-target specific criteria.
- According to a second embodiment, the present invention provides a method for selecting an siRNA, said method comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; and determining the relative functionality of the at least two siRNAs.
- According to a third embodiment, the present invention also provides a method for selecting an siRNA wherein said selection criteria are embodied in a formula comprising:
(−14)*G13−13*A1−12*U7−11*U2−10*A11−10*U4−10*C3−10*C5−10*C6−9*A10−9*U9−9*C18−8*G10−7*U1−7*U16−7*C17−7*C19+7*U17+8*A2+8*A4+8*A5+8*C4+9*G8+10*A7+10*U18+11*A19+11*C9+15*G1+18*A3+19*U10−Tm−3*(GCtotal)−6*(GC15-19)−30*X; or Formula VIII:
(−8)*A1+(−1)*A2+(12)*A3+(7)*A4+(18)*A5+(12)*A6+(19)*A7+(6)*A8+(−4)*A9+(−5)*A10+(−2)*A11+(−5)*A12+(17)*A13+(−3)*A14+(4)*A15+(2)*A16+(8)*A17+(11)*A18+(30)*A19+(−13)*U1+(−10)*U2+(2)*U3+(−2)*U4+(−5)*U5+(5)*U6+(−2)*U7+(−10)*U8+(−5)*U9+(15)*U10+(−1)*U11+(0)*U12+(10)*U13+(−9)*U14+(−13)*U15+(−10)*U16+(3)*U17+(9)*U18+(9)*U19+(7)*C1+(3)*C2+(−21)*C3+(5)*C4+(−9)*C5+(−20)*C6+(−18)*C7+(−5)*C8+(5)*C9+(1)*C10+(2)*C11+(−5)*C12+(−3)*C13+(−6)*C14+(−2)*C15+(−5)*C16+(−3)*C17+(−12)*C18+(−18)*C19+(14)*G1+(8)*G2+(7)*G3+(−10)*G4+(−4)*G5+(2)*G6+(1)*G7+(9)*G8+(5)*G9+(−11)*G10+(1)*G11+(9)*G12+(−24)*G13+(18)*G14+(11)*G15+(13)*G16+(−7)*G17+(−9)*G18+(−22)*G19+6*(number of A+U in position 15-19)−3*(number of G+C in whole siRNA), Formula X
wherein position numbering begins at the 5′-most position of a sense strand, and - A1=1 if A is the base at
position 1 of the sense strand, otherwise its value is 0; - A2=1 if A is the base at
position 2 of the sense strand, otherwise its value is 0; - A3=1 if A is the base at
position 3 of the sense strand, otherwise its value is 0; - A4=1 if A is the base at
position 4 of the sense strand, otherwise its value is 0; - A5=1 if A is the base at
position 5 of the sense strand, otherwise its value is 0; - A6=1 if A is the base at
position 6 of the sense strand, otherwise its value is 0; - A7=1 if A is the base at
position 7 of the sense strand, otherwise its value is 0; - A10=1 if A is the base at
position 10 of the sense strand, otherwise its value is 0; - A11=1 if A is the base at
position 11 of the sense strand, otherwise its value is 0; - A13=1 if A is the base at
position 13 of the sense strand, otherwise its value is 0; - A19=1 if A is the base at
position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0; - C3=1 if C is the base at
position 3 of the sense strand, otherwise its value is 0; - C4=1 if C is the base at
position 4 of the sense strand, otherwise its value is 0; - C5=1 if C is the base at
position 5 of the sense strand, otherwise its value is 0; - C6=1 if C is the base at
position 6 of the sense strand, otherwise its value is 0; - C7=1 if C is the base at
position 7 of the sense strand, otherwise its value is 0; - C9=1 if C is the base at
position 9 of the sense strand, otherwise its value is 0; - C17=1 if C is the base at
position 17 of the sense strand, otherwise its value is 0; - C18=1 if C is the base at
position 18 of the sense strand, otherwise its value is 0; - C19=1 if C is the base at
position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0; - G1=1 if G is the base at
position 1 on the sense strand, otherwise its value is 0; - G2=1 if G is the base at
position 2 of the sense strand, otherwise its value is 0; - G8=1 if G is the base at
position 8 on the sense strand, otherwise its value is 0; - G10=1 if G is the base at
position 10 on the sense strand, otherwise its value is 0; - G13=1 if G is the base at
position 13 on the sense strand, otherwise its value is 0; - G19=1 if G is the base at
position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0; - U1=1 if U is the base at
position 1 on the sense strand, otherwise its value is 0; - U2=1 if U is the base at
position 2 on the sense strand, otherwise its value is 0; - U3=1 if U is the base at
position 3 on the sense strand, otherwise its value is 0; - U4=1 if U is the base at
position 4 on the sense strand, otherwise its value is 0; - U7=1 if U is the base at
position 7 on the sense strand, otherwise its value is 0; - U9=1 if U is the base at
position 9 on the sense strand, otherwise its value is 0; - U10=1 if U is the base at
position 10 on the sense strand, otherwise its value is 0; - U15=1 if U is the base at
position 15 on the sense strand, otherwise its value is 0; - U16=1 if U is the base at
position 16 on the sense strand, otherwise its value is 0; - U17=1 if U is the base at
position 17 on the sense strand, otherwise its value is 0; - U18=1 if U is the base at
position 18 on the sense strand, otherwise its value is 0. - GC15-19=the number of G and C bases within positions 15-19 of the sense strand, or within positions 15-18 if the sense strand is only 18 base pairs in length;
- GCtotal=the number of G and C bases in the sense strand;
- Tm=100 if the siRNA oligo has the internal repeat longer then 4 base pairs, otherwise its value is 0; and
- X=the number of times that the same nucleotide repeats four or more times in a row.
- According to a fourth embodiment, the invention provides a method for developing an algorithm for selecting siRNA, said method comprising: (a) selecting a set of siRNA; (b) measuring gene silencing ability of each siRNA from said set; (c) determining relative functionality of each siRNA; (d) determining improved functionality by the presence or absence of at least one variable selected from the group consisting of the presence or absence of a particular nucleotide at a particular position, the total number of As and Us in positions 15-19, the number of times that the same nucleotide repeats within a given sequence, and the total number of Gs and Cs; and (e) developing an algorithm using the information of step (d).
- According to a fifth embodiment, the present invention provides a kit, wherein said kit is comprised of at least two siRNAs, wherein said at least two siRNAs comprise a first optimized siRNA and a second optimized siRNA, wherein said first optimized siRNA and said second optimized siRNA are optimized according a formula comprising Formula X.
- The present invention also provides a method for identifying a hyperfunctional siRNA, comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; determining the relative functionality of the at least two siRNAs and assigning each of the at least two siRNAs a functionality score; and selecting siRNAs from the at least two siRNAs that have a functionality score that reflects greater than 80 percent silencing at a concentration in the picomolar range, wherein said greater than 80 percent silencing endures for greater than 120 hours.
- According to a sixth embodiment, the present invention provides a hyperfunctional siRNA that is capable of silencing Bcl2.
- According to a seventh embodiment, the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence. The method comprises:
- (a) selecting a set of siRNAs;
- (b) measuring the gene silencing ability of each siRNA from said set;
- (c) determining the relative functionality of each siRNA;
- (d) determining the amount of improved functionality by the presence or absence of at least one variable selected from the group consisting of the total GC content, melting temperature of the siRNA, GC content at positions 15-19, the presence or absence of a particular nucleotide at a particular position, relative thermodynamic stability at particular positions in a duplex, and the number of times that the same nucleotide repeats within a given sequence; and
- (e) developing an algorithm using the information of step (d).
- According to this embodiment, preferably the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.
- In another embodiment, the present invention provides rationally designed siRNAs identified using the formulas above.
- In yet another embodiment, the present invention is directed to hyperfunctional siRNA.
- The ability to use the above algorithms, which are not sequence or species specific, allows for the cost-effective selection of optimized siRNAs for specific target sequences. Accordingly, there will be both greater efficiency and reliability in the use of siRNA technologies.
- In various embodiments, siRNAs that target pituitary tumor-transforming 1 (PTTG1) are provided. In various embodiments, the siRNAs are rationally designed. In various embodiments, the siRNAs are functional or hyperfunctional.
- In various embodiments, an siRNA that targets PTTG1 is provided, wherein the siRNA is selected from the group consisting of various siRNA sequences targeting PTTG1 that are disclosed herein. In various embodiments, the siRNA sequence is selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- In various embodiments, siRNA comprising a sense region and an antisense region are provided, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of siRNA sequences targeting PTTG1 that are disclosed herein. In various embodiments, the siRNA sequence is selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- In various embodiments, an siRNA comprising a sense region and an antisense region is provided, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is identical to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498. In various embodiments, the duplex region is 19-30 base pairs, and the sense region comprises a sequence that is identical to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- In various embodiments, a pool of at least two siRNAs is provided, wherein said pool comprises a first siRNA and a second siRNA, said first siRNA comprising a duplex region of length 18-30 base pairs that has a first sense region that is at least 90% similar to 18 bases of a first sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, and said second siRNA comprises a duplex region of length 18-30 base pairs that has a second sense region that is at least 90% similar to 18 bases of a second sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, wherein said first sense region and said second sense region are not identical.
- In various embodiments, the first sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, and said second sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498. In various embodiments, the duplex of said first siRNA is 19-30 base pairs, and said first sense region comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, and said duplex of said second siRNA is 19-30 base pairs and comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- In various embodiments, the duplex of said first siRNA is 19-30 base pairs and said first sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498, and said duplex of said second siRNA is 19-30 base pairs and said second region comprises a sequence that is identical to a sequence selected from the group consisting of SEQ ID NO. 438 to SEQ ID NO. 498.
- For a better understanding of the present invention together with other and further advantages and embodiments, reference is made to the following description taken in conjunction with the examples, the scope of which is set forth in the appended claims.
-
FIG. 1 shows a model for siRNA-RISC interactions. RISC has the ability to interact with either end of the siRNA or miRNA molecule. Following binding, the duplex is unwound, and the relevant target is identified, cleaved, and released. -
FIG. 2 is a representation of the functionality of two hundred and seventy siRNA duplexes that were generated to target human cyclophilin, human diazepam-binding inhibitor (DB), and firefly luciferase. -
FIG. 3 a is a representation of the silencing effect of 30 siRNAs in three different cells lines, HEK293, DU145, and Hela.FIG. 3 b shows the frequency of different functional groups (>95% silencing (black), >80% silencing (gray), >50% silencing (dark gray), and <50% silencing (white)) based on GC content. In cases where a given bar is absent from a particular GC percentage, no siRNA were identified for that particular group.FIG. 3 c shows the frequency of different functional groups based on melting temperature (Tm). -
FIGS. 4A-4E are representations of a statistical analysis that revealed correlations between silencing and five sequence-related properties of siRNA: (A) an A atposition 19 of the sense strand, (B) an A atposition 3 of the sense strand, (C) a U atposition 10 of the sense strand, (D) a base other than G atposition 13 of the sense strand, and (E) a base other than C atposition 19 of the sense strand. All variables were correlated with siRNA silencing of firefly luciferase and human cyclophilin. siRNAs satisfying the criterion are grouped on the left (Selected) while those that do not, are grouped on the right (Eliminated). Y-axis is “% Silencing of Control.” Each position on the X-axis represents a unique siRNA. -
FIGS. 5A and 5B are representations of firefly luciferase and cyclophilin siRNA panels sorted according to functionality and predicted values using Formula VIII. The siRNA found within the circle represent those that have Formula VIII values (SMARTSCORES™, or siRNA rank) above zero. siRNA outside the indicated area have calculated Formula VIII values that are below zero. Y-axis is “Expression (% Control).” Each position on the X-axis represents a unique siRNA. -
FIG. 6A is a representation of the average internal stability profile (AISP) derived from 270 siRNAs taken from three separate genes (cyclophilin B, DBI and firefly luciferase). Graphs represent AISP values of highly functional, functional, and non-functional siRNA.FIG. 6B is a comparison between the AISP of naturally derived GFP siRNA (filled squares) and the AISP of siRNA from cyclophilin B, DBI, and luciferase having >90% silencing properties (no fill) for the antisense strand. “DG” is the symbol for ΔG, free energy. -
FIG. 7 is a histogram showing the differences in duplex functionality upon introduction of base pair mismatches. The X-axis shows the mismatch introduced in the siRNA and the position it is introduced (e.g., 8C>A reveals that position 8 (which normally has a C) has been changed to an A). The Y-axis is “% Silencing (Normalized to Control).” The samples on the X-axis represent siRNAs at 100 nM and are, reading from left to right: 1A to C, 1A to G, 1A to U; 2A to C, 2A to G, 2A to U; 3A to C, 3A to G, 3A to U; 4G to A, 4G to C; 4G to U; 5U to A, 5U to C, 5U to G; 6U to A, 6U to C, 6U to G; 7G to A, 7G to C, 7G to U; 8C to A, 8C to G, 8C to U; 9G to A, 9G to C, 9G to U; 10C to A, 10C to G, 10C to U; 11G to A, 11G to C, 11G to U; 12G to A, 12G to C, 12G to U; 13A to C, 13A to G, 13A to U; 14G to A, 14G to C, 14G to U; 15G to A, 15G to C, 15G to U; 16A to C, 16A to G, 16A to U; 17G to A, 17G to C, 17G to U; 18U to A, 18U to C, 18U to G; 19U to A, 19U to C, 19U to G; 20 wt; Control. -
FIG. 8A is histogram that shows the effects of 5′sense and antisense strand modification with 2′-O-methylation on functionality.FIG. 8B is an expression profile showing a comparison of sense strand off-target effects for IGF1R-3 and 2′-O-methyl IGF1R-3. Sense strand off-targets (lower box) are not induced when the 5′ end of the sense strand is modified with 2′-O-methyl groups (top box). -
FIG. 9 shows a graph of SMARTSCORES™, or siRNA rank, versus RNAi silencing values for more than 360 siRNA directed against 30 different genes. SiRNA to the right of the vertical bar represent those siRNA that have desirable SMARTSCORES™, or siRNA rank. - FIGS. 10A-E compare the RNAi of five different genes (SEAP, DBI, PLK, Firefly Luciferase, and Renilla Luciferase) by varying numbers of randomly selected siRNA and four rationally designed (SMART-selected) siRNA chosen using the algorithm described in Formula VIII. In addition, RNAi induced by a pool of the four SMART-selected siRNA is reported at two different concentrations (100 and 400 nM). 10F is a comparison between a pool of randomly selected EGFR siRNA (Pool 1) and a pool of SMART-selected EGFR siRNA (Pool 2).
Pool 1, S1-S4 andPool 2 S1-S4 represent the individual members that made up each respective pool. Note that numbers for random siRNAs represent the position of the 5′ end of the sense strand of the duplex. The Y-axis represents the % expression of the control(s). The X-axis is the percent expression of the control. -
FIG. 11 shows the Western blot results from cells treated with siRNA directed against twelve different genes involved in the clathrin-dependent endocytosis pathway (CHC, DynII, CALM, CLCa, CLCb, Eps15, Eps15R, Rab5a, Rab5b, Rab5c, β2 subunit of AP-2 and EEA.1). siRNA were selected using Formula VIII. “Pool” represents a mixture of duplexes 1-4. Total concentration of each siRNA in the pool is 25 nM. Total concentration=4×25=100 nM. -
FIG. 12 is a representation of the gene silencing capabilities of rationally-selected siRNA directed against ten different genes (human and mouse cyclophilin, C-myc, human lamin A/C, QB (ubiquinol-cytochrome c reductase core protein I), MEK1 and MEK2, ATE1 (arginyl-tRNA protein transferase), GAPDH, and Eg5). The Y-axis is the percent expression of the control.Numbers -
FIG. 13 is the sequence of the top ten Bcl2 siRNAs as determined by Formula VIII. Sequences are listed 5′ to 3′. -
FIG. 14 is the knockdown by the top ten Bcl2 siRNAs at 100 nM concentrations. The Y-axis represents the amount of expression relative to the non-specific (ns) and transfection mixture control. -
FIG. 15 represents a functional walk where siRNA beginning on every other base pair of a region of the luciferase gene are tested for the ability to silence the luciferase gene. The Y-axis represents the percent expression relative to a control. The X-axis represents the position of each individual siRNA. Reading from left to right across the X-axis, the position designations are 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid. -
FIGS. 16A and 16B are histograms demonstrating the inhibition of target gene expression by pools of 2 (16A) and 3 (16B) siRNA duplexes taken from the walk described inFIG. 15 . The Y-axis in each represents the percent expression relative to control. The X-axis in each represents the position of the first siRNA in paired pools, or trios of siRNAs. For instance, the first paired pool containssiRNAs siRNAs siRNAs -
FIGS. 17A and 17B are histograms demonstrating the inhibition of target gene expression by pools of 4 (17A) and 5 (17B) siRNA duplexes. The Y-axis in each represents the percent expression relative to control. The X-axis in each represents the position of the first siRNA in each pool. For each of 17A and 17B, the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid. -
FIGS. 18A and 18B are histograms demonstrating the inhibition of target gene expression by siRNAs that are ten (18A) and twenty (18B) base pairs base pairs apart. The Y-axis represents the percent expression relative to a control. The X-axis represents the position of the first siRNA in each pool. For each of 18A and 18B, the X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid. -
FIG. 19 shows that pools of siRNAs (dark gray bar) work as well (or better) than the best siRNA in the pool (light gray bar). The Y-axis represents the percent expression relative to a control. The X-axis represents the position of the first siRNA in each pool. The X-axis from left to right reads 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, and Plasmid. -
FIG. 20 shows that the combination of several semifunctional siRNAs (dark gray) result in a significant improvement of gene expression inhibition over individual (semi-functional; light gray) siRNA. The Y-axis represents the percent expression relative to a control. -
FIGS. 21A, 21B and 21C show both pools (Library, Lib) and individual siRNAs in inhibition of gene expression of Beta-Galactosidase, Renilla Luciferase and SEAP (alkaline phosphatase). Numbers on the X-axis indicate the position of the 5′-most nucleotide of the sense strand of the duplex. The Y-axis represents the percent expression of each gene relative to a control. Libraries contain 19 nucleotide long siRNAs (not including overhangs) that begin at the following nucleotides: SEAP: Lib 1: 206, 766, 812, 923, Lib 2: 1117, 1280, 1300, 1487, Lib 3: 206, 766, 812, 923, 1117, 1280, 1300, 1487, Lib 4: 206, 812, 1117, 1300, Lib 5: 766, 923, 1280, 1487, Lib 6: 206, 1487; Bgal: Lib 1: 979, 1339, 2029, 2590, Lib 2: 1087, 1783, 2399, 3257, Lib 3: 979, 1783, 2590, 3257, Lib 4: 979, 1087, 1339, 1783, 2029, 2399, 2590, 3257, Lib 5: 979, 1087, 1339, 1783, Lib 6: 2029, 2399, 2590, 3257; Renilla: Lib 1: 174, 300, 432, 568, Lib 2: 592, 633, 729, 867, Lib 3: 174, 300, 432, 568, 592, 633, 729, 867, Lib 4: 174, 432, 592, 729, Lib 5: 300, 568, 633, 867, Lib 6: 592, 568. -
FIG. 22 shows the results of an EGFR and TfnR internalization assay when single gene knockdowns are performed. The Y-axis represents percent internalization relative to control. -
FIG. 23 shows the results of an EGFR and TfnR internalization assay when multiple genes are knocked down (e.g., Rab5a, b, c). The Y-axis represents the percent internalization relative to control. -
FIG. 24 shows the simultaneous knockdown of four different genes. siRNAs directed against G6PD, GAPDH, PLK, and UQC were simultaneously introduced into cells. Twenty-four hours later, cultures were harvested and assayed for mRNA target levels for each of the four genes. A comparison is made between cells transfected with individual siRNAs vs. a pool of siRNAs directed against all four genes. -
FIG. 25 shows the functionality of ten siRNAs at 0.3 nM concentrations. - Definitions
- Unless stated otherwise, the following terms and phrases have the meanings provided below:
- Complementary
- The term “complementary” refers to the ability of polynucleotides to form base pairs with one another. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes. As persons skilled in the art are aware, when using RNA as opposed to DNA, uracil rather than thymine is the base that is considered to be complementary to adenosine. However, when a U is denoted in the context of the present invention, the ability to substitute a T is implied, unless otherwise stated.
- Perfect complementarity or 100% complementarity refers to the situation in which each nucleotide unit of one polynucleotide strand can hydrogen bond with a nucleotide unit of a second polynucleotide strand. Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands can hydrogen bond with each other. For example, for two 20-mers, if only two base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 10% complementarity. In the same example, if 18 base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 90% complementarity.
- Deoxynucleotide
- The term “deoxynucleotide” refers to a nucleotide or polynucleotide lacking a hydroxyl group (OH group) at the 2′ and/or 3′ position of a sugar moiety. Instead, it has a hydrogen bonded to the 2′ and/or 3′ carbon. Within an RNA molecule that comprises one or more deoxynucleotides, “deoxynucleotide” refers to the lack of an OH group at the 2′ position of the sugar moiety, having instead a hydrogen bonded directly to the 2′ carbon.
- Deoxyribonucleotide
- The terms “deoxyribonucleotide” and “DNA” refer to a nucleotide or polynucleotide comprising at least one sugar moiety that has an H, rather than an OH, at its 2′ and/or 3′position.
- Duplex Region
- The phrase “duplex region” refers to the region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a stabilized duplex between polynucleotide strands that are complementary or substantially complementary. For example, a polynucleotide strand having 21 nucleotide units can base pair with another polynucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex region” has 19 base pairs. The remaining bases may, for example, exist as 5′ and 3′ overhangs. Further, within the duplex region, 100% complementarity is not required; substantial complementarity is allowable within a duplex region. Substantial complementarity refers to 79% or greater complementarity. For example, a mismatch in a duplex region consisting of 19 base pairs results in 94.7% complementarity, rendering the duplex region substantially complementary.
- Filters
- The term “filter” refers to one or more procedures that are performed on sequences that are identified by the algorithm. In some instances, filtering includes in silico procedures where sequences identified by the algorithm can be screened to identify duplexes carrying desirable or undesirable motifs. Sequences carrying such motifs can be selected for, or selected against, to obtain a final set with the preferred properties. In other instances, filtering includes wet lab experiments. For instance, sequences identified by one or more versions of the algorithm can be screened using any one of a number of procedures to identify duplexes that have hyperfunctional traits (e.g., they exhibit a high degree of silencing at subnanomolar concentrations and/or exhibit high degrees of silencing longevity).
- Gene Silencing
- The phrase “gene silencing” refers to a process by which the expression of a specific gene product is lessened or attenuated. Gene silencing can take place by a variety of pathways. Unless specified otherwise, as used herein, gene silencing refers to decreases in gene product expression that results from RNA interference (RNAi), a defined, though partially characterized pathway whereby small inhibitory RNA (siRNA) act in concert with host proteins (e.g., the RNA induced silencing complex, RISC) to degrade messenger RNA (mRNA) in a sequence-dependent fashion. The level of gene silencing can be measured by a variety of means, including, but not limited to, measurement of transcript levels by Northern Blot Analysis, B-DNA techniques, transcription-sensitive reporter constructs, expression profiling (e.g., DNA chips), and related technologies. Alternatively, the level of silencing can be measured by assessing the level of the protein encoded by a specific gene. This can be accomplished by performing a number of studies including Western Analysis, measuring the levels of expression of a reporter protein that has e.g., fluorescent properties (e.g., GFP) or enzymatic activity (e.g., alkaline phosphatases), or several other procedures.
- miRNA
- The term “miRNA” refers to microRNA.
- Nucleotide
- The term “nucleotide” refers to a ribonucleotide or a deoxyribonucleotide or modified form thereof, as well as an analog thereof. Nucleotides include species that comprise purines, e.g., adenine, hypoxanthine, guanine, and their derivatives and analogs, as well as pyrimidines, e.g., cytosine, uracil, thymine, and their derivatives and analogs.
- Nucleotide analogs include nucleotides having modifications in the chemical structure of the base, sugar and/or phosphate, including, but not limited to, 5-position pyrimidine modifications, 8-position purine modifications, modifications at cytosine exocyclic amines, and substitution of 5-bromo-uracil; and 2′-position sugar modifications, including but not limited to, sugar-modified ribonucleotides in which the 2′-OH is replaced by a group such as an H, OR, R, halo, SH, SR, NH2, NHR, NR2, or CN, wherein R is an alkyl moiety. Nucleotide analogs are also meant to include nucleotides with bases such as inosine, queuosine, xanthine, sugars such as 2′-methyl ribose, non-natural phosphodiester linkages such as methylphosphonates, phosphorothioates and peptides.
- Modified bases refer to nucleotide bases such as, for example, adenine, guanine, cytosine, thymine, uracil, xanthine, inosine, and queuosine that have been modified by the replacement or addition of one or more atoms or groups. Some examples of types of modifications that can comprise nucleotides that are modified with respect to the base moieties include but are not limited to, alkylated, halogenated, thiolated, aminated, amidated, or acetylated bases, individually or in combination. More specific examples include, for example, 5-propynyluridine, 5-propynylcytidine, 6-methyladenine, 6-methylguanine, N,N,-dimethyladenine, 2-propyladenine, 2-propylguanine, 2-aminoadenine, 1-methylinosine, 3-methyluridine, 5-methylcytidine, 5-methyluridine and other nucleotides having a modification at the 5 position, 5-(2-amino)propyl uridine, 5-halocytidine, 5-halouridine, 4-acetylcytidine, 1-methyladenosine, 2-methyladenosine, 3-methylcytidine, 6-methyluridine, 2-methylguanosine, 7-methylguanosine, 2,2-dimethylguanosine, 5-methylaminoethyluridine, 5-methyloxyuridine, deazanucleotides such as 7-deaza-adenosine, 6-azouridine, 6-azocytidine, 6-azothymidine, 5-methyl-2-thiouridine, other thio bases such as 2-thiouridine and 4-thiouridine and 2-thiocytidine, dihydrouridine, pseudouridine, queuosine, archaeosine, naphthyl and substituted naphthyl groups, any O- and N-alkylated purines and pyrimidines such as N6-methyladenosine, 5-methylcarbonylmethyluridine, uridine 5-oxyacetic acid, pyridine-4-one, pyridine-2-one, phenyl and modified phenyl groups such as aminophenol or 2,4,6-trimethoxy benzene, modified cytosines that act as G-clamp nucleotides, 8-substituted adenines and guanines, 5-substituted uracils and thymines, azapyrimidines, carboxyhydroxyalkyl nucleotides, carboxyalkylaminoalkyl nucleotides, and alkylcarbonylalkylated nucleotides. Modified nucleotides also include those nucleotides that are modified with respect to the sugar moiety, as well as nucleotides having sugars or analogs thereof that are not ribosyl. For example, the sugar moieties may be, or be based on, mannoses, arabinoses, glucopyranoses, galactopyranoses, 4′-thioribose, and other sugars, heterocycles, or carbocycles.
- The term nucleotide is also meant to include what are known in the art as universal bases. By way of example, universal bases include but are not limited to 3-nitropyrrole, 5-nitroindole, or nebularine. The term “nucleotide” is also meant to include the N3′ to P5′ phosphoramidate, resulting from the substitution of a
ribosyl 3′ oxygen with an amine group. - Further, the term nucleotide also includes those species that have a detectable label, such as for example a radioactive or fluorescent moiety, or mass label attached to the nucleotide.
- Off-Target Silencing and Off-Target Interference
- The phrases “off-target silencing” and “off-target interference” are defined as degradation of mRNA other than the intended target mRNA due to overlapping and/or partial homology with secondary mRNA messages.
- Polynucleotide
- The term “polynucleotide” refers to polymers of nucleotides, and includes but is not limited to DNA, RNA, DNA/RNA hybrids including polynucleotide chains of regularly and/or irregularly alternating deoxyribosyl moieties and ribosyl moieties (i.e., wherein alternate nucleotide units have an —OH, then and —H, then an —OH, then an —H, and so on at the 2′ position of a sugar moiety), and modifications of these kinds of polynucleotides, wherein the attachment of various entities or moieties to the nucleotide units at any position are included.
- Polyribonucleotide
- The term “polyribonucleotide” refers to a polynucleotide comprising two or more modified or unmodified ribonucleotides and/or their analogs. The term “polyribonucleotide” is used interchangeably with the term “oligoribonucleotide.”
- Ribonucleotide and Ribonucleic Acid
- The term “ribonucleotide” and the phrase “ribonucleic acid” (RNA), refer to a modified or unmodified nucleotide or polynucleotide comprising at least one ribonucleotide unit. A ribonucleotide unit comprises an hydroxyl group attached to the 2′ position of a ribosyl moiety that has a nitrogenous base attached in N-glycosidic linkage at the 1′ position of a ribosyl moiety, and a moiety that either allows for linkage to another nucleotide or precludes linkage.
- siRNA
- The term “siRNA” refers to small inhibitory RNA duplexes that induce the RNA interference (RNAi) pathway. These molecules can vary in length (generally 18-30 base pairs) and contain varying degrees of complementarity to their target mRNA in the antisense strand. Some, but not all, siRNA have unpaired overhanging bases on the 5′ or 3′ end of the sense strand and/or the antisense strand. The term “siRNA” includes duplexes of two separate strands, as well as single strands that can form hairpin structures comprising a duplex region.
- siRNA may be divided into five (5) groups (non-functional, semi-functional, functional, highly functional, and hyper-functional) based on the level or degree of silencing that they induce in cultured cell lines. As used herein, these definitions are based on a set of conditions where the siRNA is transfected into said cell line at a concentration of 100 nM and the level of silencing is tested at a time of roughly 24 hours after transfection, and not exceeding 72 hours after transfection. In this context, “non-functional siRNA” are defined as those siRNA that induce less than 50% (<50%) target silencing. “Semi-functional siRNA” induce 50-79% target silencing. “Functional siRNA” are molecules that induce 80-95% gene silencing. “Highly-functional siRNA” are molecules that induce greater than 95% gene silencing. “Hyperfunctional siRNA” are a special class of molecules. For purposes of this document, hyperfunctional siRNA are defined as those molecules that: (1) induce greater than 95% silencing of a specific target when they are transfected at subnanomolar concentrations (i.e., less than one nanomolar); and/or (2) induce functional (or better) levels of silencing for greater than 96 hours. These relative functionalities (though not intended to be absolutes) may be used to compare siRNAs to a particular target for applications such as functional genomics, target identification and therapeutics.
- SMARTSCORE™, or siRNA Rank
- The term “SMARTSCORE™”, or “siRNA rank” refers to a number determined by applying any of the formulas to a given siRNA sequence. The term “SMART-selected” or “rationally selected” or “rational selection” refers to siRNA that have been selected on the basis of their SMARTSCORES™, or siRNA ranking.
- Substantially Similar
- The phrase “substantially similar” refers to a similarity of at least 90% with respect to the identity of the bases of the sequence.
- Target
- The term “target” is used in a variety of different forms throughout this document and is defined by the context in which it is used. “Target mRNA” refers to a messenger RNA to which a given siRNA can be directed against. “Target sequence” and “target site” refer to a sequence within the mRNA to which the sense strand of an siRNA shows varying degrees of homology and the antisense strand exhibits varying degrees of complementarity. The phrase “siRNA target” can refer to the gene, mRNA, or protein against which an siRNA is directed. Similarly, “target silencing” can refer to the state of a gene, or the corresponding mRNA or protein.
- Transfection
- The term “transfection” refers to a process by which agents are introduced into a cell. The list of agents that can be transfected is large and includes, but is not limited to, siRNA, sense and/or anti-sense sequences, DNA encoding one or more genes and organized into an expression plasmid, proteins, protein fragments, and more. There are multiple methods for transfecting agents into a cell including, but not limited to, electroporation, calcium phosphate-based transfections, DEAE-dextran-based transfections, lipid-based transfections, molecular conjugate-based transfections (e.g., polylysine-DNA conjugates), microinjection and others.
- The present invention is directed to improving the efficiency of gene silencing by siRNA. Through the inclusion of multiple siRNA sequences that are targeted to a particular gene and/or selecting an siRNA sequence based on certain defined criteria, improved efficiency may be achieved.
- The present invention will now be described in connection with preferred embodiments. These embodiments are presented in order to aid in an understanding of the present invention and are not intended, and should not be construed, to limit the invention in any way. All alternatives, modifications and equivalents that may become apparent to those of ordinary skill upon reading this disclosure are included within the spirit and scope of the present invention.
- Furthermore, this disclosure is not a primer on RNA interference. Basic concepts known to persons skilled in the art have not been set forth in detail.
- The present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.
- According to a first embodiment, the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using non-target specific criteria. Each of the at least two siRNA duplexes of the kit complementary to a portion of the sequence of one or more target mRNAs is preferably selected using Formula X.
- According to a second embodiment, the present invention provides a method for selecting an siRNA, said method comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; and determining the relative functionality of the at least two siRNAs.
- In one embodiment, the present invention also provides a method wherein said selection criteria are embodied in a formula comprising:
(−14)*G13−13*A1−12*U7−11*U2−10*A11−10*U4−10*C3−10*C5−10*C6−9*A10−9*U9−9*C18−8*G10−7*U1−7*U16−7*C17−7*C19+7*U17+8*A2+8*A4+8*A5+8*C4+9*G8+10*A7+10*U18+11*A19+11*C9+15*G1+18*A3+19*U10−Tm−3*(GCtotal)−6*(GC15-19)−30*X; or Formula VIII:
(−8)*A1+(−1)*A2+(12)*A3+(7)*A4+(18)*A5+(12)*A6+(19)*A7+(6)*A8+(−4)*A9+(−5)*A10+(−2)*A11+(−5)*A12+(17)*A13+(−3)*A14+(4)*A15+(2)*A16+(8)*A17+(11)*A18+(30)*A19+(−13)*U1+(−10)*U2+(2)*U3+(−2)*U4+(−5)*U5+(5)*U6+(−2)*U7+(−10)*U8+(−5)*U9+(15)*U10+(−1)*U11+(0)*U12+(10)*U13+(−9)*U14+(−13)*U15+(−10)*U16+(3)*U17+(9)*U18+(9)*U19+(7)*C1+(3)*C2+(−21)*C3+(5)*C4+(−9)*C5+(−20)*C6+(−18)*C7+(−5)*C8+(5)*C9+(1)*C10+(2)*C11+(−5)*C12+(−3)*C13+(−6)*C14+(−2)*C15+(−5)*C16+(−3)*C17+(−12)*C18+(−18)*C19+(14)*G1+(8)*G2+(7)*G3+(−10)*G4+(−4)*G5+(2)*G6+(1)*G7+(9)*G8+(5)*G9+(−1)*G10+(1)*G11+(9)*G12+(−24)*G13+(18)*G14+(11)*G15+(13)*G16+(−7)*G17+(−9)*G18+(−22)*G19+6*(number of A+U in position 15-19)−3*(number of G+C in whole siRNA), Formula X
wherein position numbering begins at the 5′-most position of a sense strand, and - A1=1 if A is the base at
position 1 of the sense strand, otherwise its value is 0; - A2=1 if A is the base at
position 2 of the sense strand, otherwise its value is 0; - A3=1 if A is the base at
position 3 of the sense strand, otherwise its value is 0; - A4=1 if A is the base at
position 4 of the sense strand, otherwise its value is 0; - A5=1 if A is the base at
position 5 of the sense strand, otherwise its value is 0; - A6=1 if A is the base at
position 6 of the sense strand, otherwise its value is 0; - A7=1 if A is the base at
position 7 of the sense strand, otherwise its value is 0; - A10=1 if A is the base at
position 10 of the sense strand, otherwise its value is 0; - A11=1 if A is the base at
position 11 of the sense strand, otherwise its value is 0; - A13=1 if A is the base at
position 13 of the sense strand, otherwise its value is 0; - A19=1 if A is the base at
position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0; - C3=1 if C is the base at
position 3 of the sense strand, otherwise its value is 0; - C4=1 if C is the base at
position 4 of the sense strand, otherwise its value is 0; - C5=1 if C is the base at
position 5 of the sense strand, otherwise its value is 0; - C6=1 if C is the base at
position 6 of the sense strand, otherwise its value is 0; - C7=1 if C is the base at
position 7 of the sense strand, otherwise its value is 0; - C9=1 if C is the base at
position 9 of the sense strand, otherwise its value is 0; - C17=1 if C is the base at
position 17 of the sense strand, otherwise its value is 0; - C18=1 if C is the base at
position 18 of the sense strand, otherwise its value is 0; - C19=1 if C is the base at
position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0; - G1=1 if G is the base at
position 1 on the sense strand, otherwise its value is 0; - G2=1 if G is the base at
position 2 of the sense strand, otherwise its value is 0; - G8=1 if G is the base at
position 8 on the sense strand, otherwise its value is 0; - G10=1 if G is the base at
position 10 on the sense strand, otherwise its value is 0; - G13=1 if G is the base at
position 13 on the sense strand, otherwise its value is 0; - G19=1 if G is the base at
position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0; - U1=1 if U is the base at
position 1 on the sense strand, otherwise its value is 0; - U2=1 if U is the base at
position 2 on the sense strand, otherwise its value is 0; - U3=1 if U is the base at
position 3 on the sense strand, otherwise its value is 0; - U4=1 if U is the base at
position 4 on the sense strand, otherwise its value is 0; - U7=1 if U is the base at
position 7 on the sense strand, otherwise its value is 0; - U9=1 if U is the base at
position 9 on the sense strand, otherwise its value is 0; - U10=1 if U is the base at
position 10 on the sense strand, otherwise its value is 0; - U15=1 if U is the base at
position 15 on the sense strand, otherwise its value is 0; - U16=1 if U is the base at
position 16 on the sense strand, otherwise its value is 0; - U17=1 if U is the base at
position 17 on the sense strand, otherwise its value is 0; - U18=1 if U is the base at
position 18 on the sense strand, otherwise its value is 0. - GC15-19=the number of G and C bases within positions 15-19 of the sense strand, or within positions 15-18 if the sense strand is only 18 base pairs in length;
- GCtotal=the number of G and C bases in the sense strand;
- Tm=100 if the siRNA oligo has the internal repeat longer then 4 base pairs, otherwise its value is 0; and
- X=the number of times that the same nucleotide repeats four or more times in a row.
- Any of the methods of selecting siRNA in accordance with the invention can further comprise comparing the internal stability profiles of the siRNAs to be selected, and selecting those siRNAs with the most favorable internal stability profiles. Any of the methods of selecting siRNA can further comprise selecting either for or against sequences that contain motifs that induce cellular stress. Such motifs include, for example, toxicity motifs. Any of the methods of selecting siRNA can further comprise either selecting for or selecting against sequences that comprise stability motifs.
- In another embodiment, the present invention provides a method of gene silencing, comprising introducing into a cell at least one siRNA selected according to any of the methods of the present invention. The siRNA can be introduced by allowing passive uptake of siRNA, or through the use of a vector.
- According to a third embodiment, the invention provides a method for developing an algorithm for selecting siRNA, said method comprising: (a) selecting a set of siRNA; (b) measuring gene silencing ability of each siRNA from said set; (c) determining relative functionality of each siRNA; (d) determining improved functionality by the presence or absence of at least one variable selected from the group consisting of the presence or absence of a particular nucleotide at a particular position, the total number of As and Us in positions 15-19, the number of times that the same nucleotide repeats within a given sequence, and the total number of Gs and Cs; and (e) developing an algorithm using the information of step (d).
- In another embodiment, the invention provides a method for selecting an siRNA with improved functionality, comprising using the above-mentioned algorithm to identify an siRNA of improved functionality.
- According to a fourth embodiment, the present invention provides a kit, wherein said kit is comprised of at least two siRNAs, wherein said at least two siRNAs comprise a first optimized siRNA and a second optimized siRNA, wherein said first optimized siRNA and said second optimized siRNA are optimized according a formula comprising Formula X.
- According to a fifth embodiment, the present invention provides a method for identifying a hyperfunctional siRNA, comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; determining the relative functionality of the at least two siRNAs and assigning each of the at least two siRNAs a functionality score; and selecting siRNAs from the at least two siRNAs that have a functionality score that reflects greater than 80 percent silencing at a concentration in the picomolar range, wherein said greater than 80 percent silencing endures for greater than 120 hours.
- In other embodiments, the invention provides kits and/or methods wherein the siRNA are comprised of two separate polynucleotide strands; wherein the siRNA are comprised of a single contiguous molecule such as, for example, a unimolecular siRNA (comprising, for example, either a nucleotide or non-nucleotide loop); wherein the siRNA are expressed from one or more vectors; and wherein two or more genes are silenced by a single administration of siRNA.
- According to a sixth embodiment, the present invention provides a hyperfunctional siRNA that is capable of silencing Bcl2.
- According to a seventh embodiment, the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence. The method comprises:
- (a) selecting a set of siRNAs;
- (b) measuring the gene silencing ability of each siRNA from said set;
- (c) determining the relative functionality of each siRNA;
- (d) determining the amount of improved functionality by the presence or absence of at least one variable selected from the group consisting of the total GC content, melting temperature of the siRNA, GC content at positions 15-19, the presence or absence of a particular nucleotide at a particular position, relative thermodynamic stability at particular positions in a duplex, and the number of times that the same nucleotide repeats within a given sequence; and
- (e) developing an algorithm using the information of step (d).
- According to this embodiment, preferably the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.
- In another embodiment, the present invention provides rationally designed siRNAs identified using the formulas above.
- In yet another embodiment, the present invention is directed to hyperfunctional siRNA.
- The ability to use the above algorithms, which are not sequence or species specific, allows for the cost-effective selection of optimized siRNAs for specific target sequences. Accordingly, there will be both greater efficiency and reliability in the use of siRNA technologies.
- The methods disclosed herein can be used in conjunction with comparing internal stability profiles of selected siRNAs, and designing an siRNA with a desirable internal stability profile; and/or in conjunction with a selection either for or against sequences that contain motifs that induce cellular stress, for example, cellular toxicity.
- Any of the methods disclosed herein can be used to silence one or more genes by introducing an siRNA selected, or designed, in accordance with any of the methods disclosed herein. The siRNA(s) can be introduced into the cell by any method known in the art, including passive uptake or through the use of one or more vectors.
- Any of the methods and kits disclosed herein can employ either unimolecular siRNAs, siRNAs comprised of two separate polynucleotide strands, or combinations thereof. Any of the methods disclosed herein can be used in gene silencing, where two or more genes are silenced by a single administration of siRNA(s). The siRNA(s) can be directed against two or more target genes, and administered in a single dose or single transfection, as the case may be.
- Optimizing siRNA
- According to one embodiment, the present invention provides a method for improving the effectiveness of gene silencing for use to silence a particular gene through the selection of an optimal siRNA. An siRNA selected according to this method may be used individually, or in conjunction with the first embodiment, i.e., with one or more other siRNAs, each of which may or may not be selected by this criteria in order to maximize their efficiency.
- The degree to which it is possible to select an siRNA for a given mRNA that maximizes these criteria will depend on the sequence of the mRNA itself. However, the selection criteria will be independent of the target sequence. According to this method, an siRNA is selected for a given gene by using a rational design. That said, rational design can be described in a variety of ways. Rational design is, in simplest terms, the application of a proven set of criteria that enhance the probability of identifying a functional or hyperfunctional siRNA. In one method, rationally designed siRNA can be identified by maximizing one or more of the following criteria:
- (1) A low GC content, preferably between about 30-52%.
- (2) At least 2, preferably at least 3 A or U bases at positions 15-19 of the siRNA on the sense strand.
- (3) An A base at
position 19 of the sense strand. - (4) An A base at
position 3 of the sense strand. - (5) A U base at
position 10 of the sense strand. - (6) An A base at
position 14 of the sense strand. - (7) A base other than C at
position 19 of the sense strand. - (8) A base other than G at
position 13 of the sense strand. - (9) A Tm, which refers to the character of the internal repeat that results in inter- or intramolecular structures for one strand of the duplex, that is preferably not stable at greater than 50° C., more preferably not stable at greater than 37° C., even more preferably not stable at greater than 30° C. and most preferably not stable at greater than 20° C.
- (10) A base other than U at
position 5 of the sense strand. - (11) A base other than A at
position 11 of the sense strand. - (12) A base other than an A at
position 1 of the sense strand. - (13) A base other than an A at
position 2 of the sense strand. - (14) An A base at
position 4 of the sense strand. - (15) An A base at
position 5 of the sense strand. - (16) An A base at
position 6 of the sense strand. - (17) An A base at
position 7 of the sense strand. - (18) An A base at
position 8 of the sense strand. - (19) A base other than an A at
position 9 of the sense strand. - (20) A base other than an A at
position 10 of the sense strand. - (21) A base other than an A at
position 11 of the sense strand. - (22) A base other than an A at
position 12 of the sense strand. - (23) An A base at
position 13 of the sense strand. - (24) A base other than an A at
position 14 of the sense strand. - (25) An A base at
position 15 of the sense strand - (26) An A base at
position 16 of the sense strand. - (27) An A base at
position 17 of the sense strand. - (28) An A base at
position 18 of the sense strand. - (29) A base other than a U at
position 1 of the sense strand. - (30) A base other than a U at
position 2 of the sense strand. - (31) A U base at
position 3 of the sense strand. - (32) A base other than a U at
position 4 of the sense strand. - (33) A base other than a U at
position 5 of the sense strand. - (34) A U base at
position 6 of the sense strand. - (35) A base other than a U at
position 7 of the sense strand. - (36) A base other than a U at
position 8 of the sense strand. - (37) A base other than a U at
position 9 of the sense strand. - (38) A base other than a U at
position 11 of the sense strand. - (39) A U base at
position 13 of the sense strand. - (40) A base other than a U at
position 14 of the sense strand. - (41) A base other than a U at
position 15 of the sense strand. - (42) A base other than a U at
position 16 of the sense strand. - (43) A U base at
position 17 of the sense strand. - (44) A U base at
position 18 of the sense strand. - (45) A U base at
position 19 of the sense strand. - (46) A C base at
position 1 of the sense strand. - (47) A C base at
position 2 of the sense strand. - (48) A base other than a C at
position 3 of the sense strand. - (49) A C base at
position 4 of the sense strand. - (50) A base other than a C at
position 5 of the sense strand. - (51) A base other than a C at
position 6 of the sense strand. - (52) A base other than a C at
position 7 of the sense strand. - (53) A base other than a C at
position 8 of the sense strand. - (54) A C base at
position 9 of the sense strand. - (55) A C base at
position 10 of the sense strand. - (56) A C base at
position 11 of the sense strand. - (57) A base other than a C at
position 12 of the sense strand. - (58) A base other than a C at
position 13 of the sense strand. - (59) A base other than a C at
position 14 of the sense strand. - (60) A base other than a C at
position 15 of the sense strand. - (61) A base other than a C at
position 16 of the sense strand. - (62) A base other than a C at
position 17 of the sense strand. - (63) A base other than a C at
position 18 of the sense strand. - (64) A G base at
position 1 of the sense strand. - (65) A G base at
position 2 of the sense strand. - (66) A G base at
position 3 of the sense strand. - (67) A base other than a G at
position 4 of the sense strand. - (68) A base other than a G at
position 5 of the sense strand. - (69) A G base at
position 6 of the sense strand. - (70) A G base at
position 7 of the sense strand. - (71) A G base at
position 8 of the sense strand. - (72) A G base at
position 9 of the sense strand. - (73) A base other than a G at
position 10 of the sense strand. - (74) A G base at
position 11 of the sense strand. - (75) A G base at
position 12 of the sense strand. - (76) A G base at
position 14 of the sense strand. - (77) A G base at
position 15 of the sense strand. - (78) A G base at
position 16 of the sense strand. - (79) A base other than a G at
position 17 of the sense strand. - (80) A base other than a G at
position 18 of the sense strand. - (81) A base other than a G at
position 19 of the sense strand. - The importance of various criteria can vary greatly. For instance, a C base at
position 10 of the sense strand makes a minor contribution to duplex functionality. In contrast, the absence of a C atposition 3 of the sense strand is very important. Accordingly, preferably an siRNA will satisfy as many of the aforementioned criteria as possible. - With respect to the criteria, GC content, as well as a high number of AU in positions 15-19 of the sense strand, may be important for easement of the unwinding of double stranded siRNA duplex. Duplex unwinding has been shown to be crucial for siRNA functionality in vivo.
- With respect to
criterion 9, the internal structure is measured in terms of the melting temperature of the single strand of siRNA, which is the temperature at which 50% of the molecules will become denatured. With respect to criteria 2-8 and 10-11, the positions refer to sequence positions on the sense strand, which is the strand that is identical to the mRNA. - In one preferred embodiment, at
least criteria least criteria least criteria - It should be noted that all of the aforementioned criteria regarding sequence position specifics are with respect to the 5′ end of the sense strand. Reference is made to the sense strand, because most databases contain information that describes the information of the mRNA. Because according to the present invention a chain can be from 18 to 30 bases in length, and the aforementioned criteria assumes a
chain 19 base pairs in length, it is important to keep the aforementioned criteria applicable to the correct bases. - When there are only 18 bases, the base pair that is not present is the base pair that is located at the 3′ of the sense strand. When there are twenty to thirty bases present, then additional bases are added at the 5′ end of the sense chain and occupy
positions −1 to −11. Accordingly, with respect to SEQ. ID NO. 0001 NNANANNNNUCNAANNNNA and SEQ. ID NO. 0028 GUCNNANANNNNUCNAANNNNA, both would have A atposition 3, A atposition 5, U atposition 10, C atposition 11, A andposition 13, A andposition 14 and A atposition 19. However, SEQ. ID NO. 0028 would also have C at position −1, U at position −2 and G at position −3. - For a 19 base pair siRNA, an optimal sequence of one of the strands may be represented below, where N is any base, A, C, G, or U:
Claims (9)
1. An siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region, said antisense region and said sense region are each 18-30 nucleotides in length and said antisense region comprises a sequence that is at least 90% complementary to a sequence selected from the group consisting of SEQ. ID NOs. 438-498.
2. An siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region and said sense region and said antisense region are each 18-30 nucleotides in length, and said antisense region comprises a sequence that is 100% complementary to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of SEQ. ID NOs. 438-498.
3. The siRNA of claim 2 , wherein each of said antisense region and said sense region are 19-30 nucleotides in length, and said antisense region comprises a sequence that is 100% complementary to said sequence selected from the group consisting of: SEQ. ID NOs. 438-498.
4. A pool of at least two siRNAs, wherein said pool comprises a first siRNA and a second siRNA, said first siRNA comprises a first antisense region and a first sense region that together form a first duplex region and each of said first antisense region and said first sense region are 18-30 nucleotides in length and said first antisense region is at least 90% complementary to 18 bases of a first sequence selected from the group consisting of: SEQ. ID NOs. 438-498 and said second siRNA comprises a second antisense region and a second sense region that together form a second duplex region and each of said second antisense region and said second sense region are 18-30 nucleotides in length and said second antisense region is at least 90% complementary to 18 bases of a second sequence selected from the group consisting of: SEQ. ID NOs. 438-498, wherein said first antisense region and said second antisense region are not identical.
5. The pool of claim 4 , wherein said first antisense region comprises a sequence that is 100% complementary to at least 18 bases of said first sequence, and said second antisense region comprises a sequence that is 100% complementary to at least 18 bases of said second sequence.
6. The pool of claim 4 , wherein said first siRNA is 19-30 nucleotides in length and said first antisense region comprises a sequence that is at least 90% complementary to said first sequence, and second siRNA is 19-30 nucleotides in length and said second antisense region comprises a sequence that is at least 90% complementary to said second sequence.
7. The pool of claim 4 , wherein said first antisense region is 19-30 nucleotides in length and said first antisense region comprises a sequence that is 100% complementary to at least 18 bases of said first sequence, and said second antisense region is 19-30 nucleotides in length and said second antisense region comprises a sequence that is 100% complementary to said second sequence.
8. The siRNA of claim 1 , wherein said antisense region and said sense region are each 19-25 nucleotides in length.
9. The siRNA of claim 4 , wherein said first antisense region, said first sense region, said second sense region and said second antisense region are each 19-25 nucleotides in length.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/811,925 US20070260051A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting pituitary tumor-transforming 1 (PTTG1) |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42613702P | 2002-11-14 | 2002-11-14 | |
US50205003P | 2003-09-10 | 2003-09-10 | |
US10/714,333 US8090542B2 (en) | 2002-11-14 | 2003-11-14 | Functional and hyperfunctional siRNA |
PCT/US2004/014885 WO2006006948A2 (en) | 2002-11-14 | 2004-05-12 | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US10/940,892 US20120052487A9 (en) | 2002-11-14 | 2004-09-14 | Methods and compositions for selecting sirna of improved functionality |
US11/811,925 US20070260051A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting pituitary tumor-transforming 1 (PTTG1) |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,333 Continuation-In-Part US8090542B2 (en) | 2002-11-14 | 2003-11-14 | Functional and hyperfunctional siRNA |
US10/940,892 Continuation-In-Part US20120052487A9 (en) | 2002-11-14 | 2004-09-14 | Methods and compositions for selecting sirna of improved functionality |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070260051A1 true US20070260051A1 (en) | 2007-11-08 |
Family
ID=38119221
Family Applications (118)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/593,100 Expired - Fee Related US7615541B2 (en) | 2002-11-14 | 2006-11-03 | siRNA targeting TIE-2 |
US11/594,530 Expired - Fee Related US7608706B2 (en) | 2002-11-14 | 2006-11-08 | siRNA targeting ras-related nuclear protein |
US11/594,666 Abandoned US20070128641A1 (en) | 2002-11-14 | 2006-11-08 | siRNA targeting hypoxia-inducible factor 1 |
US11/595,698 Expired - Fee Related US7598369B2 (en) | 2002-11-14 | 2006-11-09 | siRNA targeting histamine receptor H1 |
US11/598,179 Expired - Fee Related US7541453B2 (en) | 2002-11-14 | 2006-11-09 | siRNA targeting aquaporin 4 |
US11/729,388 Abandoned US20070185317A1 (en) | 2002-11-14 | 2007-03-28 | siRNA targeting HtrA serine peptidase 1 |
US11/729,924 Abandoned US20080015114A1 (en) | 2002-11-14 | 2007-03-29 | siRNA targeting connective tissue growth factor (CTGF) |
US11/731,894 Expired - Fee Related US7521191B2 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting connexin 43 |
US11/731,843 Expired - Fee Related US7569684B2 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting gremlin |
US11/731,875 Abandoned US20070299253A1 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting vacuolar ATPase |
US11/731,890 Abandoned US20080045703A1 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting platelet-derived growth factor receptor beta polypeptide (PDGFR) |
US11/732,457 Expired - Fee Related US7638621B2 (en) | 2002-11-14 | 2007-04-03 | siRNA targeting insulin-like growth factor 1 receptor (IGF-1R) |
US11/732,413 Abandoned US20070238868A1 (en) | 2002-11-14 | 2007-04-03 | siRNA targeting chemokine (C-X-C motif) receptor 4 (CXCR4) |
US11/732,809 Abandoned US20070255046A1 (en) | 2002-11-14 | 2007-04-04 | siRNA targeting spectrin SH3 domain binding protein 1 (SSH3BP1) |
US11/732,810 Abandoned US20070219362A1 (en) | 2002-11-14 | 2007-04-04 | siRNA targeting azurocidin 1 (Cartionic Antimicrobial protein 37) |
US11/784,536 Abandoned US20070179286A1 (en) | 2002-11-14 | 2007-04-06 | siRNA targeting testis-specific serine kinase 4 |
US11/784,559 Abandoned US20070213520A1 (en) | 2002-11-14 | 2007-04-06 | siRNA targeting calcium/calmodulin dependent protein kinase IV (CAMK4) |
US11/784,752 Abandoned US20070213521A1 (en) | 2002-11-14 | 2007-04-09 | siRNA targeting cell division cycle 25 (CDC25C) |
US11/784,756 Abandoned US20070232797A1 (en) | 2002-11-14 | 2007-04-09 | siRNA targeting cell division cycle 2-like 5(CDC2L5) |
US11/784,755 Expired - Fee Related US7550572B2 (en) | 2002-11-14 | 2007-04-09 | siRNA targeting cell division cycle 20 homolog (CDC20) |
US11/807,577 Abandoned US20070260048A1 (en) | 2002-11-14 | 2007-05-29 | siRNA targeting centromere protein E, 312kDa (CENPE) |
US11/807,486 Active 2024-07-25 US7745610B2 (en) | 2002-11-14 | 2007-05-29 | siRNA targeting cyclin dependent kinase 11 (CDK11) |
US11/807,530 Abandoned US20070255047A1 (en) | 2002-11-14 | 2007-05-29 | siRNA targeting cell division cycle 6 homolog (CDC6) |
US11/809,909 Abandoned US20070255048A1 (en) | 2002-11-14 | 2007-06-01 | siRNA targeting discoidin domain receptor family, member 1 (DDR1) |
US11/810,074 Abandoned US20070276135A1 (en) | 2002-11-14 | 2007-06-04 | siRNA targeting dual specificity phosphate 5 (DUSP5) |
US11/810,382 Abandoned US20070260047A1 (en) | 2002-11-14 | 2007-06-05 | siRNA targeting EPH receptor A4 (EPHA4) |
US11/810,384 Abandoned US20070260049A1 (en) | 2002-11-14 | 2007-06-05 | siRNA targeting MAD2 mitotic arrest deficient-like (MAD2L2) |
US11/810,383 Expired - Fee Related US7595388B2 (en) | 2002-11-14 | 2007-06-05 | siRNA targeting EPH receptor A3 (EPHA3) |
US11/810,673 Abandoned US20070293664A1 (en) | 2002-11-14 | 2007-06-06 | siRNA targeting minichromosome maintenance deficient 5 (MCM5) |
US11/810,672 Abandoned US20070255050A1 (en) | 2002-11-14 | 2007-06-06 | siRNA targeting minichromosome maintenance deficient 2, mitotin (MCM2) |
US11/811,005 Abandoned US20070265437A1 (en) | 2002-11-14 | 2007-06-07 | siRNA targeting testes development-related NYD-SP21 (NYD-SP21) |
US11/811,012 Abandoned US20070260050A1 (en) | 2002-11-14 | 2007-06-07 | siRNA targeting minichromosome maintenance deficient 7 (MCM7) |
US11/811,003 Abandoned US20070287833A1 (en) | 2002-11-14 | 2007-06-07 | siRNA targeting minichromosome maintenance deficient 6 (MCM6) |
US11/811,209 Abandoned US20080085997A1 (en) | 2002-11-14 | 2007-06-08 | siRNA targeting phosphoinositide-3-kinase, class 2, beta polypeptide (PIK3C2B) |
US11/811,424 Abandoned US20070244312A1 (en) | 2002-11-14 | 2007-06-08 | siRNA targeting phosphoinositide-3-kinase, class 2, alpha polypeptide (PIK3C2A) |
US11/811,423 Expired - Lifetime US7645870B2 (en) | 2002-11-14 | 2007-06-08 | siRNA targeting proteasome 26S subunit, non-ATPase, 10 (Gankyrin or PSMD10) |
US11/811,954 Abandoned US20070249819A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting WEE1 homolog (WEE1) |
US11/811,925 Abandoned US20070260051A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting pituitary tumor-transforming 1 (PTTG1) |
US11/811,929 Abandoned US20070255051A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting serine/threonine kinase 22B (STK22B) |
US11/811,950 Abandoned US20070260052A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting RAD1 homolog (RAD1) |
US11/818,547 Abandoned US20070255052A1 (en) | 2002-11-14 | 2007-06-14 | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US11/818,936 Expired - Lifetime US7598370B2 (en) | 2002-11-14 | 2007-06-15 | siRNA targeting polo-like kinase-1 (PLK-1) |
US11/818,938 Expired - Lifetime US7678896B2 (en) | 2002-11-14 | 2007-06-15 | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US11/880,624 Abandoned US20080027215A1 (en) | 2002-11-14 | 2007-07-23 | siRNA targeting vascular endothelial growth factor (VEGF) |
US11/880,965 Expired - Fee Related US7579458B2 (en) | 2002-11-14 | 2007-07-25 | siRNA targeting synuclein, alpha (SNCA-1) |
US11/881,772 Abandoned US20080027216A1 (en) | 2002-11-14 | 2007-07-27 | siRNA targeting sodium channel, voltage-gated, type X, alpha (SCN10A) |
US11/881,767 Abandoned US20080039617A1 (en) | 2002-11-14 | 2007-07-27 | siRNA targeting neuropeptide Y (NPY) |
US11/975,902 Abandoned US20080097091A1 (en) | 2002-11-14 | 2007-10-22 | siRNA targeting TNFalpha |
US11/977,128 Abandoned US20080097092A1 (en) | 2002-11-14 | 2007-10-23 | siRNA targeting kinases |
US11/977,347 Abandoned US20080076908A1 (en) | 2002-11-14 | 2007-10-24 | siRNA targeting nuclear receptors |
US11/977,675 Abandoned US20080071073A1 (en) | 2002-11-14 | 2007-10-25 | siRNA targeting ubiquitin ligases |
US11/977,558 Abandoned US20080097089A1 (en) | 2002-11-14 | 2007-10-25 | siRNA targeting deubiqutination enzymes |
US11/978,125 Abandoned US20080086002A1 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting secreted frizzled-related protein 1 (sFRP1) |
US11/978,107 Expired - Fee Related US7605252B2 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting kinase insert domain receptor (KDR) |
US11/978,106 Expired - Lifetime US7655789B2 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1) |
US11/978,070 Expired - Fee Related US7582746B2 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting complement component 3 (C3) |
US11/978,097 Expired - Fee Related US7638622B2 (en) | 2002-11-14 | 2007-10-26 | SiRNA targeting intercellular adhesion molecule 1 (ICAM1) |
US11/978,120 Abandoned US20080081904A1 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting carbonic anhydrase 4(CA4) |
US11/978,475 Abandoned US20080113372A1 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting glucagon receptor (GCGR) |
US11/978,457 Abandoned US20080113371A1 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting beta secretase (BACE) |
US11/978,455 Expired - Fee Related US7795421B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting apolipoprotein B (APOB) |
US11/978,487 Abandoned US20080113374A1 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting fructose-1,6-bisphosphatase 1 (FBP1) |
US11/978,398 Expired - Lifetime US7709629B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US11/978,518 Expired - Fee Related US7632938B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting superoxide dismutase 1 (SOD1) |
US11/978,476 Expired - Fee Related US7635771B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US11/980,102 Expired - Fee Related US7662950B2 (en) | 2002-11-14 | 2007-10-30 | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US11/980,263 Expired - Fee Related US7632939B2 (en) | 2002-11-14 | 2007-10-30 | siRNA targeting proto-oncogene MET |
US11/980,300 Expired - Fee Related US7592443B2 (en) | 2002-11-14 | 2007-10-30 | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US12/321,749 Expired - Fee Related US7666853B2 (en) | 2002-11-14 | 2009-01-23 | siRNA targeting connective tissue growth factor (CTGF) |
US12/322,387 Expired - Fee Related US7589191B2 (en) | 2002-11-14 | 2009-02-02 | siRNA targeting hypoxia-inducible factor 1 |
US12/455,098 Expired - Fee Related US7741470B2 (en) | 2002-11-14 | 2009-05-28 | siRNA targeting gremlin |
US12/460,876 Abandoned US20100004141A1 (en) | 2002-11-14 | 2009-07-24 | siRNA targeting polo-like Kinase-1 (PLK-1) |
US12/462,029 Expired - Fee Related US7745612B2 (en) | 2002-11-14 | 2009-07-28 | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US12/462,420 Expired - Fee Related US7737267B2 (en) | 2002-11-14 | 2009-08-04 | siRNA targeting hypoxia-inducible factor 1 |
US12/462,820 Expired - Fee Related US8022198B2 (en) | 2002-11-14 | 2009-08-10 | siRNA targeting histamine receptor H1 |
US12/584,352 Expired - Fee Related US8222395B2 (en) | 2002-11-14 | 2009-09-03 | siRNA targeting kinase insert domain receptor (KDR) |
US12/584,850 Expired - Fee Related US7897754B2 (en) | 2002-11-14 | 2009-09-11 | SiRNA targeting ras-related nuclear protein RAN |
US12/586,167 Expired - Fee Related US7855186B2 (en) | 2002-11-14 | 2009-09-17 | siRNA targeting TIE-2 |
US12/589,879 Expired - Fee Related US8039610B2 (en) | 2002-11-14 | 2009-10-29 | siRNA targeting superoxide dismutase 1 (SOD1) |
US12/590,097 Expired - Fee Related US7816512B2 (en) | 2002-11-14 | 2009-11-02 | siRNA targeting proto-oncogene MET |
US12/590,252 Expired - Fee Related US7829696B2 (en) | 2002-11-14 | 2009-11-04 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US12/592,872 Active 2024-09-09 US8304528B2 (en) | 2002-11-14 | 2009-12-03 | SiRNA targeting fructose-1, 6-bisphosphatase 1 (FBP1) |
US12/653,120 Expired - Fee Related US8022199B2 (en) | 2002-11-14 | 2009-12-08 | SiRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US12/653,402 Expired - Fee Related US7807820B2 (en) | 2002-11-14 | 2009-12-11 | siRNA targeting beta secretase (BACE) |
US12/655,107 Expired - Fee Related US7833989B2 (en) | 2002-11-14 | 2009-12-23 | siRNA targeting connective tissue growth factor (CTGF) |
US12/657,448 Expired - Lifetime US8067576B2 (en) | 2002-11-14 | 2010-01-21 | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US12/660,582 Expired - Lifetime US8247169B2 (en) | 2002-11-14 | 2010-03-01 | SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US12/798,603 Expired - Fee Related US8030476B2 (en) | 2002-11-14 | 2010-04-07 | siRNA targeting gremlin |
US12/798,802 Expired - Fee Related US7935813B2 (en) | 2002-11-14 | 2010-04-12 | siRNA target hypoxia-inducible factor 1 |
US12/798,906 Expired - Lifetime US8236942B2 (en) | 2002-11-14 | 2010-04-13 | SiRNA targeting glucagon receptor (GCGR) |
US12/799,758 Expired - Lifetime US8217162B2 (en) | 2002-11-14 | 2010-04-30 | siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4) |
US12/799,975 Abandoned US20100267587A1 (en) | 2002-11-14 | 2010-05-05 | siRNA targeting cyclin dependent kinase 11 (CDK11) |
US12/804,014 Expired - Fee Related US8071754B2 (en) | 2002-11-14 | 2010-07-12 | siRNA targeting apolipoprotein B (APOB) |
US12/806,570 Expired - Fee Related US7999097B2 (en) | 2002-11-14 | 2010-08-17 | siRNA targeting beta secretase (BACE) |
US12/807,526 Expired - Fee Related US8222396B2 (en) | 2002-11-14 | 2010-09-08 | SiRNA targeting proto-oncogene MET |
US12/924,078 Expired - Lifetime US8268985B2 (en) | 2002-11-14 | 2010-09-20 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US12/924,653 Expired - Fee Related US8138329B2 (en) | 2002-11-14 | 2010-10-01 | siRNA targeting connective tissue growth factor (CTGF) |
US12/927,144 Expired - Fee Related US8314229B2 (en) | 2002-11-14 | 2010-11-08 | siRNA targeting tie-2 |
US13/135,336 Expired - Lifetime US8293887B2 (en) | 2002-11-14 | 2011-07-01 | SiRNA targeting beta secretase (BACE) |
US13/136,780 Expired - Fee Related US8633306B2 (en) | 2002-11-14 | 2011-08-10 | SiRNA targeting histamine receptor H1 |
US13/136,812 Expired - Fee Related US8426579B2 (en) | 2002-11-14 | 2011-08-11 | SiRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US13/199,240 Abandoned US20110319297A1 (en) | 2002-11-14 | 2011-08-23 | siRNA targeting gremlin |
US13/199,946 Abandoned US20120015850A1 (en) | 2002-11-14 | 2011-09-13 | siRNA targeting Superoxide |
US13/317,752 Expired - Lifetime US8232386B2 (en) | 2002-11-14 | 2011-10-27 | SiRNA targeting apolipoprotein B (APOB) |
US13/385,320 Expired - Fee Related US8461326B2 (en) | 2002-11-14 | 2012-02-14 | SiRNA targeting connective tissue growth factor (CTGF) |
US13/489,725 Abandoned US20120252873A1 (en) | 2002-11-14 | 2012-06-06 | siRNA Targeting Interleukin-1 Receptor-associated Kinase 4 (IRAK4) |
US13/494,360 Abandoned US20120258888A1 (en) | 2002-11-14 | 2012-06-12 | siRNA Targeting Proto-oncogene MET |
US13/524,015 Expired - Fee Related US8575329B2 (en) | 2002-11-14 | 2012-06-15 | siRNA targeting kinase insert domain receptor (KDR) |
US13/536,005 Expired - Fee Related US8445668B2 (en) | 2002-11-14 | 2012-06-28 | SiRNA targeting apolipoprotein (APOB) |
US13/539,630 Abandoned US20120270751A1 (en) | 2002-11-14 | 2012-07-02 | siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2 (DGAT2) |
US13/542,332 Abandoned US20120283311A1 (en) | 2002-11-14 | 2012-07-05 | siRNA Targeting Glucagon Receptor (GCCR) |
US13/551,794 Expired - Fee Related US8658784B2 (en) | 2002-11-14 | 2012-07-18 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US13/613,910 Abandoned US20130023446A1 (en) | 2002-11-14 | 2012-09-13 | siRNA Targeting Beta Secretase (BACE) |
US13/632,519 Abandoned US20130059760A1 (en) | 2002-11-14 | 2012-10-01 | siRNA Targeting Fructose-1, 6-bisphosphatase 1 (FBP1) |
US13/647,869 Expired - Fee Related US8658785B1 (en) | 2002-11-14 | 2012-10-09 | siRNA targeting tie-2 |
US13/847,544 Expired - Fee Related US8883998B2 (en) | 2002-11-14 | 2013-03-20 | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US13/867,175 Abandoned US20130225447A1 (en) | 2002-11-14 | 2013-04-22 | siRNA Targeting Apolipoprotein B (APOB) |
US14/099,339 Expired - Fee Related US8907077B2 (en) | 2002-11-14 | 2013-12-06 | siRNA targeting TIE-2 |
Family Applications Before (37)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/593,100 Expired - Fee Related US7615541B2 (en) | 2002-11-14 | 2006-11-03 | siRNA targeting TIE-2 |
US11/594,530 Expired - Fee Related US7608706B2 (en) | 2002-11-14 | 2006-11-08 | siRNA targeting ras-related nuclear protein |
US11/594,666 Abandoned US20070128641A1 (en) | 2002-11-14 | 2006-11-08 | siRNA targeting hypoxia-inducible factor 1 |
US11/595,698 Expired - Fee Related US7598369B2 (en) | 2002-11-14 | 2006-11-09 | siRNA targeting histamine receptor H1 |
US11/598,179 Expired - Fee Related US7541453B2 (en) | 2002-11-14 | 2006-11-09 | siRNA targeting aquaporin 4 |
US11/729,388 Abandoned US20070185317A1 (en) | 2002-11-14 | 2007-03-28 | siRNA targeting HtrA serine peptidase 1 |
US11/729,924 Abandoned US20080015114A1 (en) | 2002-11-14 | 2007-03-29 | siRNA targeting connective tissue growth factor (CTGF) |
US11/731,894 Expired - Fee Related US7521191B2 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting connexin 43 |
US11/731,843 Expired - Fee Related US7569684B2 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting gremlin |
US11/731,875 Abandoned US20070299253A1 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting vacuolar ATPase |
US11/731,890 Abandoned US20080045703A1 (en) | 2002-11-14 | 2007-03-30 | siRNA targeting platelet-derived growth factor receptor beta polypeptide (PDGFR) |
US11/732,457 Expired - Fee Related US7638621B2 (en) | 2002-11-14 | 2007-04-03 | siRNA targeting insulin-like growth factor 1 receptor (IGF-1R) |
US11/732,413 Abandoned US20070238868A1 (en) | 2002-11-14 | 2007-04-03 | siRNA targeting chemokine (C-X-C motif) receptor 4 (CXCR4) |
US11/732,809 Abandoned US20070255046A1 (en) | 2002-11-14 | 2007-04-04 | siRNA targeting spectrin SH3 domain binding protein 1 (SSH3BP1) |
US11/732,810 Abandoned US20070219362A1 (en) | 2002-11-14 | 2007-04-04 | siRNA targeting azurocidin 1 (Cartionic Antimicrobial protein 37) |
US11/784,536 Abandoned US20070179286A1 (en) | 2002-11-14 | 2007-04-06 | siRNA targeting testis-specific serine kinase 4 |
US11/784,559 Abandoned US20070213520A1 (en) | 2002-11-14 | 2007-04-06 | siRNA targeting calcium/calmodulin dependent protein kinase IV (CAMK4) |
US11/784,752 Abandoned US20070213521A1 (en) | 2002-11-14 | 2007-04-09 | siRNA targeting cell division cycle 25 (CDC25C) |
US11/784,756 Abandoned US20070232797A1 (en) | 2002-11-14 | 2007-04-09 | siRNA targeting cell division cycle 2-like 5(CDC2L5) |
US11/784,755 Expired - Fee Related US7550572B2 (en) | 2002-11-14 | 2007-04-09 | siRNA targeting cell division cycle 20 homolog (CDC20) |
US11/807,577 Abandoned US20070260048A1 (en) | 2002-11-14 | 2007-05-29 | siRNA targeting centromere protein E, 312kDa (CENPE) |
US11/807,486 Active 2024-07-25 US7745610B2 (en) | 2002-11-14 | 2007-05-29 | siRNA targeting cyclin dependent kinase 11 (CDK11) |
US11/807,530 Abandoned US20070255047A1 (en) | 2002-11-14 | 2007-05-29 | siRNA targeting cell division cycle 6 homolog (CDC6) |
US11/809,909 Abandoned US20070255048A1 (en) | 2002-11-14 | 2007-06-01 | siRNA targeting discoidin domain receptor family, member 1 (DDR1) |
US11/810,074 Abandoned US20070276135A1 (en) | 2002-11-14 | 2007-06-04 | siRNA targeting dual specificity phosphate 5 (DUSP5) |
US11/810,382 Abandoned US20070260047A1 (en) | 2002-11-14 | 2007-06-05 | siRNA targeting EPH receptor A4 (EPHA4) |
US11/810,384 Abandoned US20070260049A1 (en) | 2002-11-14 | 2007-06-05 | siRNA targeting MAD2 mitotic arrest deficient-like (MAD2L2) |
US11/810,383 Expired - Fee Related US7595388B2 (en) | 2002-11-14 | 2007-06-05 | siRNA targeting EPH receptor A3 (EPHA3) |
US11/810,673 Abandoned US20070293664A1 (en) | 2002-11-14 | 2007-06-06 | siRNA targeting minichromosome maintenance deficient 5 (MCM5) |
US11/810,672 Abandoned US20070255050A1 (en) | 2002-11-14 | 2007-06-06 | siRNA targeting minichromosome maintenance deficient 2, mitotin (MCM2) |
US11/811,005 Abandoned US20070265437A1 (en) | 2002-11-14 | 2007-06-07 | siRNA targeting testes development-related NYD-SP21 (NYD-SP21) |
US11/811,012 Abandoned US20070260050A1 (en) | 2002-11-14 | 2007-06-07 | siRNA targeting minichromosome maintenance deficient 7 (MCM7) |
US11/811,003 Abandoned US20070287833A1 (en) | 2002-11-14 | 2007-06-07 | siRNA targeting minichromosome maintenance deficient 6 (MCM6) |
US11/811,209 Abandoned US20080085997A1 (en) | 2002-11-14 | 2007-06-08 | siRNA targeting phosphoinositide-3-kinase, class 2, beta polypeptide (PIK3C2B) |
US11/811,424 Abandoned US20070244312A1 (en) | 2002-11-14 | 2007-06-08 | siRNA targeting phosphoinositide-3-kinase, class 2, alpha polypeptide (PIK3C2A) |
US11/811,423 Expired - Lifetime US7645870B2 (en) | 2002-11-14 | 2007-06-08 | siRNA targeting proteasome 26S subunit, non-ATPase, 10 (Gankyrin or PSMD10) |
US11/811,954 Abandoned US20070249819A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting WEE1 homolog (WEE1) |
Family Applications After (80)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/811,929 Abandoned US20070255051A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting serine/threonine kinase 22B (STK22B) |
US11/811,950 Abandoned US20070260052A1 (en) | 2002-11-14 | 2007-06-12 | siRNA targeting RAD1 homolog (RAD1) |
US11/818,547 Abandoned US20070255052A1 (en) | 2002-11-14 | 2007-06-14 | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US11/818,936 Expired - Lifetime US7598370B2 (en) | 2002-11-14 | 2007-06-15 | siRNA targeting polo-like kinase-1 (PLK-1) |
US11/818,938 Expired - Lifetime US7678896B2 (en) | 2002-11-14 | 2007-06-15 | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US11/880,624 Abandoned US20080027215A1 (en) | 2002-11-14 | 2007-07-23 | siRNA targeting vascular endothelial growth factor (VEGF) |
US11/880,965 Expired - Fee Related US7579458B2 (en) | 2002-11-14 | 2007-07-25 | siRNA targeting synuclein, alpha (SNCA-1) |
US11/881,772 Abandoned US20080027216A1 (en) | 2002-11-14 | 2007-07-27 | siRNA targeting sodium channel, voltage-gated, type X, alpha (SCN10A) |
US11/881,767 Abandoned US20080039617A1 (en) | 2002-11-14 | 2007-07-27 | siRNA targeting neuropeptide Y (NPY) |
US11/975,902 Abandoned US20080097091A1 (en) | 2002-11-14 | 2007-10-22 | siRNA targeting TNFalpha |
US11/977,128 Abandoned US20080097092A1 (en) | 2002-11-14 | 2007-10-23 | siRNA targeting kinases |
US11/977,347 Abandoned US20080076908A1 (en) | 2002-11-14 | 2007-10-24 | siRNA targeting nuclear receptors |
US11/977,675 Abandoned US20080071073A1 (en) | 2002-11-14 | 2007-10-25 | siRNA targeting ubiquitin ligases |
US11/977,558 Abandoned US20080097089A1 (en) | 2002-11-14 | 2007-10-25 | siRNA targeting deubiqutination enzymes |
US11/978,125 Abandoned US20080086002A1 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting secreted frizzled-related protein 1 (sFRP1) |
US11/978,107 Expired - Fee Related US7605252B2 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting kinase insert domain receptor (KDR) |
US11/978,106 Expired - Lifetime US7655789B2 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1) |
US11/978,070 Expired - Fee Related US7582746B2 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting complement component 3 (C3) |
US11/978,097 Expired - Fee Related US7638622B2 (en) | 2002-11-14 | 2007-10-26 | SiRNA targeting intercellular adhesion molecule 1 (ICAM1) |
US11/978,120 Abandoned US20080081904A1 (en) | 2002-11-14 | 2007-10-26 | siRNA targeting carbonic anhydrase 4(CA4) |
US11/978,475 Abandoned US20080113372A1 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting glucagon receptor (GCGR) |
US11/978,457 Abandoned US20080113371A1 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting beta secretase (BACE) |
US11/978,455 Expired - Fee Related US7795421B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting apolipoprotein B (APOB) |
US11/978,487 Abandoned US20080113374A1 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting fructose-1,6-bisphosphatase 1 (FBP1) |
US11/978,398 Expired - Lifetime US7709629B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US11/978,518 Expired - Fee Related US7632938B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting superoxide dismutase 1 (SOD1) |
US11/978,476 Expired - Fee Related US7635771B2 (en) | 2002-11-14 | 2007-10-29 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US11/980,102 Expired - Fee Related US7662950B2 (en) | 2002-11-14 | 2007-10-30 | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US11/980,263 Expired - Fee Related US7632939B2 (en) | 2002-11-14 | 2007-10-30 | siRNA targeting proto-oncogene MET |
US11/980,300 Expired - Fee Related US7592443B2 (en) | 2002-11-14 | 2007-10-30 | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US12/321,749 Expired - Fee Related US7666853B2 (en) | 2002-11-14 | 2009-01-23 | siRNA targeting connective tissue growth factor (CTGF) |
US12/322,387 Expired - Fee Related US7589191B2 (en) | 2002-11-14 | 2009-02-02 | siRNA targeting hypoxia-inducible factor 1 |
US12/455,098 Expired - Fee Related US7741470B2 (en) | 2002-11-14 | 2009-05-28 | siRNA targeting gremlin |
US12/460,876 Abandoned US20100004141A1 (en) | 2002-11-14 | 2009-07-24 | siRNA targeting polo-like Kinase-1 (PLK-1) |
US12/462,029 Expired - Fee Related US7745612B2 (en) | 2002-11-14 | 2009-07-28 | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US12/462,420 Expired - Fee Related US7737267B2 (en) | 2002-11-14 | 2009-08-04 | siRNA targeting hypoxia-inducible factor 1 |
US12/462,820 Expired - Fee Related US8022198B2 (en) | 2002-11-14 | 2009-08-10 | siRNA targeting histamine receptor H1 |
US12/584,352 Expired - Fee Related US8222395B2 (en) | 2002-11-14 | 2009-09-03 | siRNA targeting kinase insert domain receptor (KDR) |
US12/584,850 Expired - Fee Related US7897754B2 (en) | 2002-11-14 | 2009-09-11 | SiRNA targeting ras-related nuclear protein RAN |
US12/586,167 Expired - Fee Related US7855186B2 (en) | 2002-11-14 | 2009-09-17 | siRNA targeting TIE-2 |
US12/589,879 Expired - Fee Related US8039610B2 (en) | 2002-11-14 | 2009-10-29 | siRNA targeting superoxide dismutase 1 (SOD1) |
US12/590,097 Expired - Fee Related US7816512B2 (en) | 2002-11-14 | 2009-11-02 | siRNA targeting proto-oncogene MET |
US12/590,252 Expired - Fee Related US7829696B2 (en) | 2002-11-14 | 2009-11-04 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US12/592,872 Active 2024-09-09 US8304528B2 (en) | 2002-11-14 | 2009-12-03 | SiRNA targeting fructose-1, 6-bisphosphatase 1 (FBP1) |
US12/653,120 Expired - Fee Related US8022199B2 (en) | 2002-11-14 | 2009-12-08 | SiRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US12/653,402 Expired - Fee Related US7807820B2 (en) | 2002-11-14 | 2009-12-11 | siRNA targeting beta secretase (BACE) |
US12/655,107 Expired - Fee Related US7833989B2 (en) | 2002-11-14 | 2009-12-23 | siRNA targeting connective tissue growth factor (CTGF) |
US12/657,448 Expired - Lifetime US8067576B2 (en) | 2002-11-14 | 2010-01-21 | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US12/660,582 Expired - Lifetime US8247169B2 (en) | 2002-11-14 | 2010-03-01 | SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US12/798,603 Expired - Fee Related US8030476B2 (en) | 2002-11-14 | 2010-04-07 | siRNA targeting gremlin |
US12/798,802 Expired - Fee Related US7935813B2 (en) | 2002-11-14 | 2010-04-12 | siRNA target hypoxia-inducible factor 1 |
US12/798,906 Expired - Lifetime US8236942B2 (en) | 2002-11-14 | 2010-04-13 | SiRNA targeting glucagon receptor (GCGR) |
US12/799,758 Expired - Lifetime US8217162B2 (en) | 2002-11-14 | 2010-04-30 | siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4) |
US12/799,975 Abandoned US20100267587A1 (en) | 2002-11-14 | 2010-05-05 | siRNA targeting cyclin dependent kinase 11 (CDK11) |
US12/804,014 Expired - Fee Related US8071754B2 (en) | 2002-11-14 | 2010-07-12 | siRNA targeting apolipoprotein B (APOB) |
US12/806,570 Expired - Fee Related US7999097B2 (en) | 2002-11-14 | 2010-08-17 | siRNA targeting beta secretase (BACE) |
US12/807,526 Expired - Fee Related US8222396B2 (en) | 2002-11-14 | 2010-09-08 | SiRNA targeting proto-oncogene MET |
US12/924,078 Expired - Lifetime US8268985B2 (en) | 2002-11-14 | 2010-09-20 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US12/924,653 Expired - Fee Related US8138329B2 (en) | 2002-11-14 | 2010-10-01 | siRNA targeting connective tissue growth factor (CTGF) |
US12/927,144 Expired - Fee Related US8314229B2 (en) | 2002-11-14 | 2010-11-08 | siRNA targeting tie-2 |
US13/135,336 Expired - Lifetime US8293887B2 (en) | 2002-11-14 | 2011-07-01 | SiRNA targeting beta secretase (BACE) |
US13/136,780 Expired - Fee Related US8633306B2 (en) | 2002-11-14 | 2011-08-10 | SiRNA targeting histamine receptor H1 |
US13/136,812 Expired - Fee Related US8426579B2 (en) | 2002-11-14 | 2011-08-11 | SiRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US13/199,240 Abandoned US20110319297A1 (en) | 2002-11-14 | 2011-08-23 | siRNA targeting gremlin |
US13/199,946 Abandoned US20120015850A1 (en) | 2002-11-14 | 2011-09-13 | siRNA targeting Superoxide |
US13/317,752 Expired - Lifetime US8232386B2 (en) | 2002-11-14 | 2011-10-27 | SiRNA targeting apolipoprotein B (APOB) |
US13/385,320 Expired - Fee Related US8461326B2 (en) | 2002-11-14 | 2012-02-14 | SiRNA targeting connective tissue growth factor (CTGF) |
US13/489,725 Abandoned US20120252873A1 (en) | 2002-11-14 | 2012-06-06 | siRNA Targeting Interleukin-1 Receptor-associated Kinase 4 (IRAK4) |
US13/494,360 Abandoned US20120258888A1 (en) | 2002-11-14 | 2012-06-12 | siRNA Targeting Proto-oncogene MET |
US13/524,015 Expired - Fee Related US8575329B2 (en) | 2002-11-14 | 2012-06-15 | siRNA targeting kinase insert domain receptor (KDR) |
US13/536,005 Expired - Fee Related US8445668B2 (en) | 2002-11-14 | 2012-06-28 | SiRNA targeting apolipoprotein (APOB) |
US13/539,630 Abandoned US20120270751A1 (en) | 2002-11-14 | 2012-07-02 | siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2 (DGAT2) |
US13/542,332 Abandoned US20120283311A1 (en) | 2002-11-14 | 2012-07-05 | siRNA Targeting Glucagon Receptor (GCCR) |
US13/551,794 Expired - Fee Related US8658784B2 (en) | 2002-11-14 | 2012-07-18 | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US13/613,910 Abandoned US20130023446A1 (en) | 2002-11-14 | 2012-09-13 | siRNA Targeting Beta Secretase (BACE) |
US13/632,519 Abandoned US20130059760A1 (en) | 2002-11-14 | 2012-10-01 | siRNA Targeting Fructose-1, 6-bisphosphatase 1 (FBP1) |
US13/647,869 Expired - Fee Related US8658785B1 (en) | 2002-11-14 | 2012-10-09 | siRNA targeting tie-2 |
US13/847,544 Expired - Fee Related US8883998B2 (en) | 2002-11-14 | 2013-03-20 | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US13/867,175 Abandoned US20130225447A1 (en) | 2002-11-14 | 2013-04-22 | siRNA Targeting Apolipoprotein B (APOB) |
US14/099,339 Expired - Fee Related US8907077B2 (en) | 2002-11-14 | 2013-12-06 | siRNA targeting TIE-2 |
Country Status (2)
Country | Link |
---|---|
US (118) | US7615541B2 (en) |
WO (1) | WO2006006948A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10125369B2 (en) | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
US10851377B2 (en) | 2015-08-25 | 2020-12-01 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Families Citing this family (245)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2950073A (en) * | 1957-02-18 | 1960-08-23 | Lockheed Aircraft Corp | Hoist mechanism |
WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
EP1478656B1 (en) | 2002-02-01 | 2009-09-16 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
WO2003106631A2 (en) * | 2002-06-12 | 2003-12-24 | Ambion, Inc. | Methods and compositions relating to labeled rna molecules that reduce gene expression |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
JP2006507841A (en) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | Functional and ultrafunctional siRNA |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
US7691998B2 (en) * | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
WO2005035561A1 (en) * | 2003-10-14 | 2005-04-21 | University College Cork - National University Of Ireland, Cork | Igf-i responsive gene and use thereof |
US8088902B2 (en) * | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
CA2578064C (en) * | 2004-08-23 | 2015-10-13 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas |
KR101409241B1 (en) | 2004-09-28 | 2014-06-24 | 쿠아크 파마수티칼스 인코퍼레이티드 | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
US20060142228A1 (en) | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
DE102005003788A1 (en) * | 2005-01-19 | 2006-07-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | siRNA molecules for the treatment of blood vessels |
EP2662088A3 (en) * | 2005-02-03 | 2014-02-19 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
JP4131271B2 (en) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | Information processing apparatus and method, and program |
ES2538213T3 (en) * | 2005-09-20 | 2015-06-18 | J.R. Simplot Company | Foods low in acrylamide |
GB0521351D0 (en) * | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
US8258109B2 (en) * | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
EP1966379B1 (en) * | 2005-12-22 | 2010-04-28 | OPKO Ophthalmics, LLC | Compositions and methods for regulating complement system |
WO2007121156A2 (en) | 2006-04-13 | 2007-10-25 | Alcon Research, Ltd | Rnai-mediated inhibition of histamine receptor h1-related conditions |
TW200808360A (en) | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
WO2007147067A2 (en) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
CN101517081A (en) * | 2006-08-24 | 2009-08-26 | 爱尔康研究有限公司 | RNAi-mediated inhibition of Gremlin for treatment of IOP-related conditions |
US20080214486A1 (en) * | 2006-11-28 | 2008-09-04 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS |
US20100292471A1 (en) * | 2006-12-18 | 2010-11-18 | Panagene Inc. | Peptide nucleic acid oligomers comprising universal bases,preparation methods thereof, and kits, devices and methods for the analysis, detection or modulation of nucleic acids using the same |
US20100015706A1 (en) * | 2007-03-02 | 2010-01-21 | Mdrna, Inc. | Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof |
US8232085B2 (en) | 2007-03-14 | 2012-07-31 | Bionsil S.R.L. | Isoform of bruton's tyrosine kinase (BTK) protein |
US8843675B2 (en) * | 2007-03-15 | 2014-09-23 | Broadcom Corporation | Pipelined buffer interconnect |
US8906632B2 (en) * | 2007-03-23 | 2014-12-09 | Korea University Research & Business Foundation | Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma |
SI2170403T1 (en) | 2007-06-27 | 2014-07-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
TW200911290A (en) * | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
BRPI0814189A2 (en) | 2007-07-05 | 2015-03-03 | Novartis Ag | DOUBLE FILM RIBONUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND ITS USES, METHOD FOR INHIBITING PHOSPHYDYLINOSITOL 4-KINASE EXPRESSION, VECTOR AND USE OF A COMPOUND THAT SELECTIVELY INHIBITS PHOSPHTIDYLINOSITOL-4 PHASE. |
US7910722B2 (en) * | 2007-07-05 | 2011-03-22 | Florida State University Research Foundation | RNAi therapeutic for treatment of hepatitis C infection |
JP2010532662A (en) * | 2007-07-06 | 2010-10-14 | イントラダイム コーポレイション | Methods and compositions for the treatment of cancer and other angiogenesis related diseases |
US20110160279A1 (en) * | 2007-08-13 | 2011-06-30 | Board Of Trustees Of Southern Illinois University | METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
AU2008343839A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions |
US20110092449A1 (en) * | 2007-12-21 | 2011-04-21 | Bradford James Duft | Treatment of fibrotic conditions |
WO2009085273A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
EP2237786A2 (en) | 2007-12-21 | 2010-10-13 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
EP2077335A1 (en) * | 2007-12-22 | 2009-07-08 | Universitätsklinikum Schleswig-Holstein | EXO1 promoter polymorphism associated with exceptional life expectancy in humans |
US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
EP2075333A1 (en) * | 2007-12-28 | 2009-07-01 | Qiagen GmbH | Positive controls for expression modulating experiments |
WO2009097077A2 (en) * | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
US9173896B2 (en) * | 2008-02-15 | 2015-11-03 | Arrowhead Research Corporation | RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions |
WO2009113579A1 (en) * | 2008-03-11 | 2009-09-17 | 学校法人埼玉医科大学 | Double-stranded nucleic acid molecule suitable for prevention or treatment of cancer, cancer cell proliferation inhibitor, and pharmaceutical preparation |
DK2279254T3 (en) | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION |
KR101707669B1 (en) * | 2008-04-17 | 2017-02-16 | 더 존스 홉킨스 유니버시티 | On01910. na enhances chemotherapeutic agent activity in drug-resistant cancers |
US8217161B2 (en) * | 2008-04-22 | 2012-07-10 | Clemson University Research Foundation | Methods of inhibiting multiple cytochrome P450 genes with siRNA |
DE102008029669A1 (en) * | 2008-05-16 | 2009-11-19 | Schlaak, Jörg Friedrich, Prof. Dr. med. | New therapeutics for hepatitis therapy |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
WO2010027279A2 (en) * | 2008-09-04 | 2010-03-11 | Genesis Research And Development Corporation Limited | Compositions and methods for the treatment and prevention of neoplastic disorders |
AU2009293658A1 (en) | 2008-09-22 | 2010-03-25 | James Cardia | Reduced size self-delivering RNAi compounds |
EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
US9095592B2 (en) * | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2010107952A2 (en) * | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20110045080A1 (en) * | 2009-03-24 | 2011-02-24 | William Marsh Rice University | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto |
JP2012521765A (en) * | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of intracellular adhesion molecule 1 (ICAM-1) gene expression using small interfering nucleic acids (siNA) |
WO2010113037A1 (en) * | 2009-04-03 | 2010-10-07 | Centre National De La Recherche Scientifique | Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements |
WO2010144611A2 (en) * | 2009-06-10 | 2010-12-16 | 3-V Biosciences, Inc. | Antivirals that target transporters, carriers, and ion channels |
CN101851625B (en) * | 2009-06-25 | 2012-07-18 | 上海交通大学 | RNA interference sequences of glucagon receptor gene |
CN101586103B (en) * | 2009-06-25 | 2010-12-08 | 上海交通大学 | RNA interference sequence of glucagon receptor gene |
CN101851624B (en) * | 2009-06-25 | 2012-04-18 | 上海交通大学 | RNA interference sequences of glucagon receptor gene |
ES2613498T3 (en) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | New lipid formulations for the delivery of therapeutic agents to solid tumors |
US10165286B2 (en) | 2009-07-08 | 2018-12-25 | Dejero Labs Inc. | System and method for automatic encoder adjustment based on transport data |
US9222086B2 (en) * | 2009-09-23 | 2015-12-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
US20110152343A1 (en) * | 2009-12-22 | 2011-06-23 | Functional Genetics, Inc. | Protease inhibitors and broad-spectrum antiviral |
US20130023578A1 (en) * | 2009-12-31 | 2013-01-24 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of c-Met expression and anticancer composition containing the same |
DK2521556T3 (en) | 2010-01-08 | 2018-08-13 | Ionis Pharmaceuticals Inc | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION |
CN102102101A (en) * | 2010-03-05 | 2011-06-22 | 重庆医科大学 | SiRNA for inhibiting expression of Plk1 and use thereof |
FR2957426B1 (en) * | 2010-03-12 | 2012-03-02 | Thales Sa | AUTONOMOUS PSEUDOLITE POSITIONING SYSTEM IN THE CONSTRAINED ZONE AND METHOD OF IMPLEMENTING THE SAME |
CN106074591B (en) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | RNA interference in ocular symptoms |
CN105131067B (en) * | 2010-03-24 | 2019-02-19 | 雷克西制药公司 | RNA in skin and fibrotic conditions is interfered |
EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
WO2011146732A1 (en) * | 2010-05-19 | 2011-11-24 | Beth Israel Deaconess Medical Center | Methods for treating inflammatory autoimmune disorders |
EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US9074721B2 (en) | 2010-06-09 | 2015-07-07 | Alex Lau | Support system |
US9316346B2 (en) | 2010-06-09 | 2016-04-19 | Colebrook Bosson Saunders (Products) Limited | Support system |
EP2585596B1 (en) * | 2010-06-23 | 2020-12-30 | CuRNA, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
EP2598639A4 (en) | 2010-07-28 | 2014-08-13 | Alcon Res Ltd | Sirna targeting vegfa and methods for treatment in vivo |
USD684982S1 (en) | 2010-08-11 | 2013-06-25 | Colebrook Bosson Saunders (Products) Limited | Display support with indicator window |
WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
WO2012034942A1 (en) | 2010-09-13 | 2012-03-22 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase b expression |
CA2818662C (en) | 2010-10-22 | 2021-07-06 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid molecule inducing rna interference, and uses thereof |
US9587033B2 (en) | 2010-11-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting TNK-1 |
WO2012068405A2 (en) * | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
US20150247148A1 (en) * | 2011-01-31 | 2015-09-03 | Kyowa Hakko Kirin Co., Ltd. | Composition for suppressing expression of target gene |
EP2670411B1 (en) | 2011-02-02 | 2019-04-10 | Excaliard Pharmaceuticals, Inc. | Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars |
US8658783B2 (en) | 2011-04-13 | 2014-02-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
JP6024025B2 (en) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | Ultrafiltration concentration of allotype-selected antibodies for small volume administration |
US8802839B2 (en) | 2011-07-15 | 2014-08-12 | Fibrogen, Inc. | Connective tissue growth factor antisense oligonucleotides |
EP3366302B1 (en) * | 2011-07-18 | 2021-12-08 | University Of Kentucky Research Foundation | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
WO2013056670A1 (en) | 2011-10-19 | 2013-04-25 | 苏州瑞博生物技术有限公司 | Small interference rnas, uses thereof and method for inhibiting the expression of plk1 gene |
US20140286965A1 (en) | 2011-11-07 | 2014-09-25 | Inserm | Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
EP2592146A3 (en) * | 2011-11-14 | 2013-07-24 | Silenseed Ltd | Methods and compositions for treating prostate cancer |
US9617331B2 (en) | 2011-11-27 | 2017-04-11 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide |
US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
WO2013123996A1 (en) * | 2012-02-24 | 2013-08-29 | Astrazeneca Uk Limited | Novel sirna inhibitors of human icam-1 |
SG11201405157PA (en) | 2012-02-24 | 2014-10-30 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
EP2819703A4 (en) * | 2012-02-29 | 2015-11-18 | Benitec Biopharma Ltd | Pain treatment |
AU2013232855B2 (en) * | 2012-03-15 | 2016-10-27 | Hyun Kee Kim | Gremlin-1 antibody |
DE202012003753U1 (en) * | 2012-04-13 | 2013-07-17 | Joseph Vögele AG | Cross distribution arrangement for a paver |
CN102690826B (en) * | 2012-04-19 | 2014-03-05 | 山西医科大学 | shRNA for specifically reducing human Aurora-A gene expression and application thereof |
JP6139671B2 (en) * | 2012-05-22 | 2017-05-31 | オリックス ファーマシューティカルズ インコーポレイテッドOlix Pharmaceuticals Inc. | Nucleic acid molecule that induces RNA interference with intracellular penetration ability and use thereof |
US9353422B2 (en) * | 2012-06-04 | 2016-05-31 | Academia Sinica | USP37 inactivation as a treatment for PLZF/RARA-associated acute promyelocytic leukemia |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
EP2893018B1 (en) | 2012-09-05 | 2019-07-24 | Sylentis S.A.U. | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
ES2967530T3 (en) * | 2012-10-26 | 2024-04-30 | Palomo Ltd | Compositions and methods for the treatment of Parkinson's disease by selective administration of oligonucleotide molecules to specific types of neurons |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
CA2897390A1 (en) | 2013-01-10 | 2014-07-17 | Ge Healthcare Dharmacon, Inc. | Templates, libraries, kits and methods for generating molecules |
WO2014115158A1 (en) * | 2013-01-28 | 2014-07-31 | Council Of Scientific & Industrial Research | METHOD FOR INHIBITING TUMOR GROWTH THROUGH RNA-INTERFERENCE USING LIPOSOMALLY ASSOCIATED CDC20 siRNA |
CA2906663A1 (en) | 2013-03-15 | 2014-09-18 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
EP2968603B1 (en) | 2013-03-15 | 2020-06-24 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
RU2015154721A (en) | 2013-05-22 | 2017-06-27 | Элнилэм Фармасьютикалз, Инк. | RNAi SERPINA1 COMPOSITIONS AND WAYS OF THEIR APPLICATION |
EP4012031A1 (en) | 2013-07-03 | 2022-06-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna |
CN105683377B (en) * | 2013-07-05 | 2019-05-21 | 柏业公司 | Respiratory disorder related gene specific siRNA, the double helix widow RNA structure containing siRNA are used to preventing or treating respiratory disorder containing their compositions |
KR20150006742A (en) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same |
TW201536329A (en) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression |
ES2790574T3 (en) | 2013-08-28 | 2020-10-28 | Ionis Pharmaceuticals Inc | Prekallikrein expression modulation (PKK) |
US10150965B2 (en) | 2013-12-06 | 2018-12-11 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA |
KR20210158880A (en) * | 2013-12-12 | 2021-12-31 | 알닐람 파마슈티칼스 인코포레이티드 | Complement component irna compositions and methods of use thereof |
CN111440795A (en) | 2013-12-24 | 2020-07-24 | Ionis制药公司 | Modulation of angiopoietin-like 3 expression |
DK3087184T3 (en) | 2013-12-27 | 2019-07-29 | Dicerna Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF GLYCOLATE TOXIDASE (HAO1) WITH DOUBLE-STRENGTH RNA |
WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
JP6447933B2 (en) | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ,インコーポレイテッド | Disease treatment by inducing an immune response against Trop-2 expressing cells |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
EP3126499B1 (en) | 2014-04-01 | 2020-06-24 | Biogen MA Inc. | Compositions for modulating sod-1 expression |
KR20150137473A (en) * | 2014-05-29 | 2015-12-09 | 한국과학기술연구원 | siRNA for Inhibition of USP15 Expression and Pharmaceutical Composition Containing the same |
CA2952289A1 (en) | 2014-07-10 | 2016-01-14 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of usher syndrome type 2 |
CN107532199B (en) * | 2014-07-29 | 2021-10-22 | 威马克生物有限公司 | Novel biomarker for predicting sensitivity associated with mesenchymal epithelial transformation factor inhibitor and use thereof |
CN114010788A (en) | 2014-08-22 | 2022-02-08 | 奥克兰联合服务有限公司 | Channel modulators |
CN104258377B (en) * | 2014-09-10 | 2017-06-30 | 中南大学湘雅医院 | Application of the PIK3C2A albumen in liver-cancer medicine is treated |
WO2016057932A1 (en) | 2014-10-10 | 2016-04-14 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
CN112410339A (en) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | Regulatory polynucleotides |
JP2017535266A (en) | 2014-11-14 | 2017-11-30 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Compositions and methods for treating amyotrophic lateral sclerosis (ALS) |
JP2017537619A (en) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes |
CN104450710B (en) * | 2014-11-28 | 2018-06-05 | 广州市锐博生物科技有限公司 | Inhibit nucleic acid oligomer and its application of MYD88 genes |
US10036017B2 (en) | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
CN104673799B (en) * | 2015-03-09 | 2019-02-05 | 浙江大学 | It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug |
US10689647B2 (en) | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
WO2017053781A1 (en) | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
JP7027311B2 (en) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ,インコーポレーテッド | Treatment of age-related macular degeneration with RNA complexes targeting MyD88 or TLR3 |
SG10201913085TA (en) | 2015-12-07 | 2020-02-27 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
WO2017100193A1 (en) * | 2015-12-10 | 2017-06-15 | Fibrogen, Inc. | Methods for treatment of motor neuron diseases |
CN105462978B (en) * | 2015-12-18 | 2018-05-15 | 中国科学院北京基因组研究所 | One species specificity suppresses siRNA and its application of MAGEA1 gene expressions |
CN105462977B (en) * | 2015-12-18 | 2018-05-11 | 中国科学院北京基因组研究所 | One species specificity suppresses siRNA and its application of MAGEA1 gene expressions |
WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
EP3411480A4 (en) | 2016-02-02 | 2020-01-22 | Olix Pharmaceuticals, Inc. | TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4R , TRPA1, OR F2RL1 |
JP7003044B2 (en) | 2016-02-02 | 2022-01-20 | オリックス ファーマシューティカルズ,インコーポレーテッド | Treatment of angiogenesis-related diseases with RNA complexes targeting ANGPT2 and PDGFB |
US10301628B2 (en) | 2016-04-11 | 2019-05-28 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11479818B2 (en) * | 2016-06-17 | 2022-10-25 | Hoffmann-La Roche Inc. | In vitro nephrotoxicity screening assay |
KR101916652B1 (en) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | Compounds improving RNA interference of small interfering RNA and use thereof |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
JOP20190104A1 (en) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
TWI788312B (en) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3554342A1 (en) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
US11591600B2 (en) | 2017-02-10 | 2023-02-28 | OliX Pharmaceuticals. Inc. | Long double-stranded RNA for RNA interference |
DE102017206836A1 (en) * | 2017-04-24 | 2018-10-25 | Zf Friedrichshafen Ag | Transmission for a motor vehicle |
CA3061738A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
SG11201909870SA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
EP3681513A4 (en) | 2017-09-14 | 2021-09-22 | Arrowhead Pharmaceuticals, Inc. | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
CN111182913A (en) * | 2017-10-02 | 2020-05-19 | 西奈医疗中心 | Methods and compositions for effective delivery through multiple biological barriers |
KR102609396B1 (en) | 2017-10-13 | 2023-12-01 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods and compositions for inhibiting expression of LDHA |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
EP4124658A3 (en) | 2017-10-16 | 2023-04-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
TWI809004B (en) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use |
WO2019105418A1 (en) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
KR102443358B1 (en) | 2017-12-06 | 2022-09-14 | 어비디티 바이오사이언시스 인크. | Compositions and methods for treating muscular dystrophy and myotonic dystrophy |
CN111512160B (en) | 2017-12-21 | 2024-04-09 | 豪夫迈·罗氏有限公司 | Companion diagnosis of HTRA1 RNA antagonists |
CN116375774A (en) | 2017-12-29 | 2023-07-04 | 苏州瑞博生物技术股份有限公司 | Conjugate, preparation method and application thereof |
TW201938177A (en) | 2018-01-08 | 2019-10-01 | 美商艾歐凡斯生物治療公司 | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
EP3737759A1 (en) | 2018-01-12 | 2020-11-18 | Roche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotides and uses thereof |
EP3759127A4 (en) | 2018-03-02 | 2022-03-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
CA3098144A1 (en) | 2018-05-09 | 2019-11-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn3 expression |
US11162083B2 (en) | 2018-06-14 | 2021-11-02 | University Of South Carolina | Peptide based inhibitors of Raf kinase protein dimerization and kinase activity |
EP3810095A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
TWI833770B (en) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | Compounds and methods for reducing lrrk2 expression |
AU2019299861A1 (en) | 2018-07-02 | 2021-01-14 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
CN111655297A (en) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | siRNA conjugate and preparation method and application thereof |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
JP2022509809A (en) * | 2018-11-23 | 2022-01-24 | サイレンス・セラピューティクス・ゲーエムベーハー | Nucleic acid for inhibiting C3 expression in cells |
WO2021021673A1 (en) | 2019-07-26 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
EP4022060A1 (en) | 2019-08-27 | 2022-07-06 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of c3 in a cell |
CN114173783A (en) * | 2019-08-30 | 2022-03-11 | 新加坡科技研究局 | Methods of promoting survival and/or function of motor neurons and related agents, uses and methods |
CN112442500A (en) * | 2019-08-30 | 2021-03-05 | 恩智(广州)医药科技有限公司 | siRNA for inhibiting MCM7, composition and application thereof |
CN110938691B (en) * | 2019-12-03 | 2023-07-07 | 兰州大学 | Application of human DUS4L gene and related products |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
IL310900A (en) | 2020-03-19 | 2024-04-01 | Avidity Biosciences Inc | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2021195469A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
CN113444723A (en) * | 2020-03-27 | 2021-09-28 | 北京键凯科技股份有限公司 | Interfering RNA for inhibiting vascular endothelial growth factor receptor 2 gene expression and application thereof |
BR112022020020A2 (en) | 2020-04-04 | 2022-11-22 | Pfizer | METHODS OF TREATMENT OF CORONAVIRUS DISEASE 2019 |
CN116113421A (en) | 2020-05-14 | 2023-05-12 | 阿莱兹精准医疗公司 | Cancer treatment using siRNA to modulate PRDM2/RIZ protein expression |
KR102421750B1 (en) * | 2020-05-26 | 2022-07-19 | 올릭스 주식회사 | RNAi AGENTS TARGETING MYELOID DIFFERENTIATION PRIMARY RESPONSE 88 AND METHOD OF USE THEREOF |
US11459567B2 (en) | 2020-06-24 | 2022-10-04 | Patricia Virginia Elizalde | Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer |
CA3185749A1 (en) | 2020-06-29 | 2022-01-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating plp1 |
CN111849992A (en) * | 2020-08-17 | 2020-10-30 | 南通大学 | siRNA molecule of targeted c-Met gene and application thereof |
CA3189065A1 (en) | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
WO2022109398A1 (en) * | 2020-11-23 | 2022-05-27 | University Of Massachusetts | Oligonucleotides for dgat2 modulation |
WO2022136466A1 (en) * | 2020-12-23 | 2022-06-30 | Argonaute RNA Limited | Treatment of cardiovascular disease |
IL304880A (en) | 2021-02-12 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
US11578329B2 (en) | 2021-04-19 | 2023-02-14 | Novo Nordisk A/S | Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression |
EP4347820A1 (en) | 2021-05-28 | 2024-04-10 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression |
WO2023034870A2 (en) | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
WO2023133639A1 (en) * | 2022-01-13 | 2023-07-20 | University Health Network | Targeting the ythdf1 - arhgef2 axis for cancer treatment |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
WO2023158514A1 (en) | 2022-02-18 | 2023-08-24 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
WO2023245060A2 (en) | 2022-06-15 | 2023-12-21 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150945A1 (en) * | 2000-12-28 | 2002-10-17 | Cell Therapeutics, Inc. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
US20030105051A1 (en) * | 2001-05-29 | 2003-06-05 | Mcswiggen James | Nucleic acid treatment of diseases or conditions related to levels of HER2 |
US20040054155A1 (en) * | 2002-02-01 | 2004-03-18 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
US20040180357A1 (en) * | 2002-11-01 | 2004-09-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
US20050130181A1 (en) * | 2001-05-18 | 2005-06-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20050181382A1 (en) * | 2003-06-02 | 2005-08-18 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US20050186586A1 (en) * | 2003-06-02 | 2005-08-25 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US20050239731A1 (en) * | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
US20070031844A1 (en) * | 2002-11-14 | 2007-02-08 | Anastasia Khvorova | Functional and hyperfunctional siRNA |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US702831A (en) * | 1901-08-20 | 1902-06-17 | Samuel Thompson | Combined double escutcheon and paint protector. |
US760807A (en) * | 1903-11-11 | 1904-05-24 | Lee Roberts | Cutting-nippers. |
US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5741671A (en) * | 1991-12-12 | 1998-04-21 | The Johns Hopkins University | Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1) |
US6001992A (en) * | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
US20040204380A1 (en) * | 1999-01-07 | 2004-10-14 | Ackermann Elizabeth J | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
US5981175A (en) * | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
US20020086321A1 (en) * | 1993-02-02 | 2002-07-04 | Craig Ruth W. | Myeloid cell leukemia associated gene MCL-1 |
US5641756A (en) | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
US5731294A (en) | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
DK0745124T3 (en) * | 1994-02-14 | 1999-02-01 | Amgen Inc | Mammalian cell cycle protein |
WO1996000286A1 (en) * | 1994-06-27 | 1996-01-04 | Toagosei Co., Ltd. | Antisense nucleic acid compound |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
WO1997020925A1 (en) | 1995-12-08 | 1997-06-12 | Hybridon, Inc. | Modified vegf antisense oligonucleotides for treatment of skin disorders |
WO1997021808A1 (en) | 1995-12-08 | 1997-06-19 | Hybridon, Inc. | Modified vegf antisense oligonucleotides |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
AU2733697A (en) | 1996-04-17 | 1997-11-07 | Aronex Pharmaceuticals, Inc. | Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression |
US20050261485A1 (en) * | 1996-05-23 | 2005-11-24 | Toagosei Co., Ltd., A Japan Corporation | Method of producing antisense oligonucleotide |
AU3249897A (en) | 1996-07-01 | 1998-01-21 | Jim A. Wright | Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth |
WO1998027425A1 (en) | 1996-12-19 | 1998-06-25 | Isis Pharmaceuticals, Inc. | Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
JPH1142091A (en) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | Anti-sense nucleic acid compound |
US6046319A (en) * | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CA2362320A1 (en) | 1998-01-29 | 1999-08-05 | The Trustees Of Columbia University In The City Of New York | Human hairless gene, protein and uses thereof |
US6111086A (en) * | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
US20030228597A1 (en) * | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
WO1999054459A2 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
WO1999055910A1 (en) | 1998-04-24 | 1999-11-04 | Arizona Board Of Regents | Method of inducing apoptosis in a target cell |
ATE274923T1 (en) | 1998-06-10 | 2004-09-15 | Biognostik Ges | STIMULATING THE IMMUNE SYSTEM |
CA2336384A1 (en) | 1998-07-02 | 2000-01-13 | The Trustees Of Columbia University In The City Of New York | Oligonucleotide inhibitors of bcl-xl |
US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
HUP0104302A3 (en) | 1998-11-06 | 2002-11-28 | Abbott Gmbh & Co Kg | Inhibition of the formation of vascular hyperpermeability |
US20040235041A1 (en) * | 1998-11-17 | 2004-11-25 | Shimkets Richard A. | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
AU2476200A (en) | 1998-12-04 | 2000-06-19 | Immusol, Inc | Ribozyme therapy for the treatment and/or prevention of restenosis |
US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
WO2000044194A1 (en) | 1999-01-19 | 2000-07-27 | Siemens Aktiengesellschaft | Method for the time synchronisation of a computer network and computer network with time synchronisation |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
JP4638098B2 (en) | 1999-06-14 | 2011-02-23 | キャンサー・リサーチ・テクノロジー・リミテッド | Cancer treatment |
DE19928367A1 (en) * | 1999-06-21 | 2000-12-28 | Will E C H Gmbh & Co | Handling of stacked sheet materials has a facility for stacking and separating into selected stack size |
US6770633B1 (en) | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (en) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang |
US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
ATE450621T2 (en) * | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | MEDIATORS OF RNA INTERFERENCE THAT ARE RNA SEQUENCE SPECIFIC |
US6509559B1 (en) * | 2000-06-20 | 2003-01-21 | Ppt Vision, Inc. | Binary optical grating and method for generating a moire pattern for 3D imaging |
US6521258B1 (en) | 2000-09-08 | 2003-02-18 | Ferro Corporation | Polymer matrices prepared by supercritical fluid processing techniques |
AU2002210295A1 (en) | 2000-10-13 | 2002-04-22 | Institut De Cardiologie De Montreal | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
CN1312184C (en) * | 2000-11-01 | 2007-04-25 | Bki控股公司 | Cellulose ethers and method of preparing the same |
HU230458B1 (en) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Rna interference mediating small rna molecules |
JP2004532616A (en) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | Double-stranded RNA-mediated gene suppression |
US20030143597A1 (en) | 2000-12-28 | 2003-07-31 | Finney Robert E. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
EP1353676A4 (en) | 2000-12-29 | 2006-05-31 | Alteon Inc | Method for treating fibrotic diseases or other indications |
WO2003035869A1 (en) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene |
JP4080337B2 (en) * | 2001-03-22 | 2008-04-23 | 松下電器産業株式会社 | Positive electrode active material and non-aqueous electrolyte secondary battery including the same |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
WO2002085285A2 (en) * | 2001-04-18 | 2002-10-31 | Wyeth | Methods and reagents for regulating bone and cartilage formation |
AU2002305236A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
WO2002085308A2 (en) | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
US20040219671A1 (en) * | 2002-02-20 | 2004-11-04 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) |
WO2003070897A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
CN100463967C (en) * | 2001-05-29 | 2009-02-25 | 人体细胞组织有限公司 | testicular carnitine transporter and its gene |
CA2448320A1 (en) | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
US6734017B2 (en) * | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
WO2003035870A1 (en) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Drug for treating a carcinoma of the pancreas |
EP1445311A4 (en) * | 2001-10-30 | 2005-01-12 | Daiichi Seiyaku Co | Method of amplyfying hematopoietic stem cells |
JP2005527639A (en) * | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Methods and compositions for therapeutic use of RNA interference |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
FR2832154B1 (en) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE |
US20030186903A1 (en) | 2001-11-23 | 2003-10-02 | Isis Pharmaceuticals Inc. | Antisense modulation of MyD88 expression |
ES2605445T3 (en) | 2001-11-26 | 2017-03-14 | Hivih | Protein-protein interactions in the human immunodeficiency virus |
US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
KR100441894B1 (en) * | 2002-01-26 | 2004-07-27 | 한국전자통신연구원 | Micro-integrated near-field optical recording head and optical recording system using the same |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
JP2005517452A (en) | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | RNA interference-mediated inhibition of BCL2 gene expression using short interfering nucleic acids (siNA) |
AU2003224725A1 (en) * | 2002-03-20 | 2003-10-08 | Brigham And Women's Hospital, Inc. | Hiv therapeutic |
JP2005521418A (en) * | 2002-03-29 | 2005-07-21 | イェン、ユン | Human ribonucleotide reductase M2 subunit |
US20030224512A1 (en) | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
WO2003094790A2 (en) | 2002-05-13 | 2003-11-20 | Salviac Limited | Catheter system with procedural catheter and embolic proctection system |
US20040101857A1 (en) * | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of cytokine-inducible kinase expression |
AU2003283951A1 (en) * | 2002-05-23 | 2004-03-03 | Ceptyr, Inc. | Modulation of biological signal transduction by rna interference |
US20040102391A1 (en) | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Gankyrin expression |
EP1551990A4 (en) | 2002-06-18 | 2006-12-06 | Irm Llc | Diagnosis and treatment of chemoresistant tumors |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US6906186B1 (en) * | 2002-07-30 | 2005-06-14 | Isis Pharmaceuticals, Inc. | Antisense modulation of polo-like kinase expression |
GB0218010D0 (en) * | 2002-08-05 | 2002-09-11 | Ciba Spec Chem Water Treat Ltd | Production of a fermentation product |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
WO2004027030A2 (en) | 2002-09-18 | 2004-04-01 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds |
WO2004031237A1 (en) | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human myeloid leukemia |
JP2006517916A (en) * | 2002-10-30 | 2006-08-03 | ザ シービーアール インスティテュート フォー バイオメディカル リサーチ インコーポレーティッド | Methods for treating and preventing apoptosis-related diseases using RNA interference substances |
US20040192629A1 (en) * | 2002-11-04 | 2004-09-30 | University Of Massachusetts | Allele-specific RNA interference |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
US7592442B2 (en) | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US7582747B2 (en) | 2002-11-14 | 2009-09-01 | Dharmacon, Inc. | siRNA targeting inner centromere protein antigens (INCENP) |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US20040214198A1 (en) | 2002-11-15 | 2004-10-28 | University Of Massachusetts | Allele-targeted RNA interference |
US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
WO2004052920A2 (en) * | 2002-12-12 | 2004-06-24 | The Burnham Institute | Conversion of apoptotic proteins |
DE602004015064D1 (en) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF COLONY CANCER |
FR2835837B1 (en) | 2003-02-06 | 2007-03-16 | Centre Nat Rech Scient | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE ENCODING A GROWTH FACTOR |
FR2835838B1 (en) | 2003-02-06 | 2007-11-16 | Centre Nat Rech Scient | OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE ENCODING A TRANSCRIPTION FACTOR |
CA2515677A1 (en) * | 2003-02-11 | 2004-08-26 | Wyeth | Methods for monitoring drug activities in vivo |
US20040191818A1 (en) * | 2003-02-26 | 2004-09-30 | O'toole Margot Mary | Compositions and methods for diagnosing and treating autoimmune diseases |
ATE479752T1 (en) * | 2003-03-07 | 2010-09-15 | Alnylam Pharmaceuticals Inc | THERAPEUTIC COMPOSITIONS |
WO2004090105A2 (en) | 2003-04-02 | 2004-10-21 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
CA2527301A1 (en) | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
ES2712695T3 (en) | 2003-06-02 | 2019-05-14 | Univ Massachusetts | Methods and compositions to control the efficiency of RNA silencing |
US7786290B2 (en) | 2003-06-13 | 2010-08-31 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
DE10341333B4 (en) * | 2003-09-08 | 2006-06-08 | Siemens Ag | Piezoelectric actuator and method for producing a piezoelectric actuator |
KR20060131761A (en) | 2003-11-27 | 2006-12-20 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | Method and system for chapter marker and title boundary insertion in dv video |
KR100586654B1 (en) * | 2003-12-19 | 2006-06-07 | 이처닷컴 주식회사 | Wireless banking system and wireless banking method using mobile phone |
WO2005062937A2 (en) | 2003-12-22 | 2005-07-14 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna |
JP2005233933A (en) * | 2004-01-19 | 2005-09-02 | Nec Electronics Corp | Combination test method and testing device |
KR101054402B1 (en) * | 2004-02-06 | 2011-08-04 | 엘지전자 주식회사 | Pulley assembly of washing machine |
US20050176045A1 (en) | 2004-02-06 | 2005-08-11 | Dharmacon, Inc. | SNP discriminatory siRNA |
US7947659B2 (en) | 2004-03-12 | 2011-05-24 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
KR101147147B1 (en) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Modified polynucleotides for reducing off-target effects in rna interference |
AU2005238034A1 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
JP2007536253A (en) | 2004-05-04 | 2007-12-13 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | Compositions and methods for enhancing delivery of nucleic acids into cells and modifying expression of target genes in cells |
CN101052717A (en) | 2004-05-11 | 2007-10-10 | α基因株式会社 | Polynucleotide causing RNA interfere and method of regulating gene expression with the use of the same |
US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
KR101409241B1 (en) * | 2004-09-28 | 2014-06-24 | 쿠아크 파마수티칼스 인코퍼레이티드 | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
CA2587411A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
US7879992B2 (en) * | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
US7150451B2 (en) * | 2005-02-18 | 2006-12-19 | Gm Global Technology Operations, Inc. | Air spring and jounce shock assembly |
CN101277704A (en) | 2005-04-12 | 2008-10-01 | 因特拉迪格姆公司 | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
US20060286575A1 (en) * | 2005-04-16 | 2006-12-21 | Cylene Pharmaceuticals, Inc. | MCL-1 quadruplex nucleic acids and uses thereof |
US8268629B2 (en) * | 2005-06-21 | 2012-09-18 | dTEC Systems L.L.C. | Method for the measurement of water and water-soluble components in non-aqueous liquids |
EP1772274B2 (en) | 2005-09-29 | 2011-05-25 | Brother Kogyo Kabushiki Kaisha | Ink cartridge, set of ink cartridges and ink jet recording system |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
WO2007087451A2 (en) | 2006-01-25 | 2007-08-02 | University Of Massachusetts | Compositions and methods for enhancing discriminatory rna interference |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
ES2413804T3 (en) | 2006-05-19 | 2013-07-17 | Alcon Research, Ltd. | RNAi-mediated inhibition of states related to tumor necrosis factor-alpha |
US8523707B2 (en) * | 2006-05-31 | 2013-09-03 | Bridgestone Sports Co., Ltd. | Multi-piece solid golf ball |
US8138160B2 (en) | 2006-08-03 | 2012-03-20 | Warsaw Orthopedic, Inc. | Reagents, methods and systems to suppress pro-inflammatory cytokines |
CN101517081A (en) * | 2006-08-24 | 2009-08-26 | 爱尔康研究有限公司 | RNAi-mediated inhibition of Gremlin for treatment of IOP-related conditions |
JP2010507387A (en) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
SI2170403T1 (en) | 2007-06-27 | 2014-07-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
US7572747B2 (en) * | 2007-09-27 | 2009-08-11 | Alfred University | Optical glass |
AU2008306455C1 (en) | 2007-10-03 | 2014-04-17 | Quark Pharmaceuticals, Inc. | Novel siRNA structures |
CN101640467B (en) | 2008-07-28 | 2012-05-30 | 鸿富锦精密工业(深圳)有限公司 | Shrapnel and voice coil motor |
-
2004
- 2004-05-12 WO PCT/US2004/014885 patent/WO2006006948A2/en active Application Filing
-
2006
- 2006-11-03 US US11/593,100 patent/US7615541B2/en not_active Expired - Fee Related
- 2006-11-08 US US11/594,530 patent/US7608706B2/en not_active Expired - Fee Related
- 2006-11-08 US US11/594,666 patent/US20070128641A1/en not_active Abandoned
- 2006-11-09 US US11/595,698 patent/US7598369B2/en not_active Expired - Fee Related
- 2006-11-09 US US11/598,179 patent/US7541453B2/en not_active Expired - Fee Related
-
2007
- 2007-03-28 US US11/729,388 patent/US20070185317A1/en not_active Abandoned
- 2007-03-29 US US11/729,924 patent/US20080015114A1/en not_active Abandoned
- 2007-03-30 US US11/731,894 patent/US7521191B2/en not_active Expired - Fee Related
- 2007-03-30 US US11/731,843 patent/US7569684B2/en not_active Expired - Fee Related
- 2007-03-30 US US11/731,875 patent/US20070299253A1/en not_active Abandoned
- 2007-03-30 US US11/731,890 patent/US20080045703A1/en not_active Abandoned
- 2007-04-03 US US11/732,457 patent/US7638621B2/en not_active Expired - Fee Related
- 2007-04-03 US US11/732,413 patent/US20070238868A1/en not_active Abandoned
- 2007-04-04 US US11/732,809 patent/US20070255046A1/en not_active Abandoned
- 2007-04-04 US US11/732,810 patent/US20070219362A1/en not_active Abandoned
- 2007-04-06 US US11/784,536 patent/US20070179286A1/en not_active Abandoned
- 2007-04-06 US US11/784,559 patent/US20070213520A1/en not_active Abandoned
- 2007-04-09 US US11/784,752 patent/US20070213521A1/en not_active Abandoned
- 2007-04-09 US US11/784,756 patent/US20070232797A1/en not_active Abandoned
- 2007-04-09 US US11/784,755 patent/US7550572B2/en not_active Expired - Fee Related
- 2007-05-29 US US11/807,577 patent/US20070260048A1/en not_active Abandoned
- 2007-05-29 US US11/807,486 patent/US7745610B2/en active Active
- 2007-05-29 US US11/807,530 patent/US20070255047A1/en not_active Abandoned
- 2007-06-01 US US11/809,909 patent/US20070255048A1/en not_active Abandoned
- 2007-06-04 US US11/810,074 patent/US20070276135A1/en not_active Abandoned
- 2007-06-05 US US11/810,382 patent/US20070260047A1/en not_active Abandoned
- 2007-06-05 US US11/810,384 patent/US20070260049A1/en not_active Abandoned
- 2007-06-05 US US11/810,383 patent/US7595388B2/en not_active Expired - Fee Related
- 2007-06-06 US US11/810,673 patent/US20070293664A1/en not_active Abandoned
- 2007-06-06 US US11/810,672 patent/US20070255050A1/en not_active Abandoned
- 2007-06-07 US US11/811,005 patent/US20070265437A1/en not_active Abandoned
- 2007-06-07 US US11/811,012 patent/US20070260050A1/en not_active Abandoned
- 2007-06-07 US US11/811,003 patent/US20070287833A1/en not_active Abandoned
- 2007-06-08 US US11/811,209 patent/US20080085997A1/en not_active Abandoned
- 2007-06-08 US US11/811,424 patent/US20070244312A1/en not_active Abandoned
- 2007-06-08 US US11/811,423 patent/US7645870B2/en not_active Expired - Lifetime
- 2007-06-12 US US11/811,954 patent/US20070249819A1/en not_active Abandoned
- 2007-06-12 US US11/811,925 patent/US20070260051A1/en not_active Abandoned
- 2007-06-12 US US11/811,929 patent/US20070255051A1/en not_active Abandoned
- 2007-06-12 US US11/811,950 patent/US20070260052A1/en not_active Abandoned
- 2007-06-14 US US11/818,547 patent/US20070255052A1/en not_active Abandoned
- 2007-06-15 US US11/818,936 patent/US7598370B2/en not_active Expired - Lifetime
- 2007-06-15 US US11/818,938 patent/US7678896B2/en not_active Expired - Lifetime
- 2007-07-23 US US11/880,624 patent/US20080027215A1/en not_active Abandoned
- 2007-07-25 US US11/880,965 patent/US7579458B2/en not_active Expired - Fee Related
- 2007-07-27 US US11/881,772 patent/US20080027216A1/en not_active Abandoned
- 2007-07-27 US US11/881,767 patent/US20080039617A1/en not_active Abandoned
- 2007-10-22 US US11/975,902 patent/US20080097091A1/en not_active Abandoned
- 2007-10-23 US US11/977,128 patent/US20080097092A1/en not_active Abandoned
- 2007-10-24 US US11/977,347 patent/US20080076908A1/en not_active Abandoned
- 2007-10-25 US US11/977,675 patent/US20080071073A1/en not_active Abandoned
- 2007-10-25 US US11/977,558 patent/US20080097089A1/en not_active Abandoned
- 2007-10-26 US US11/978,125 patent/US20080086002A1/en not_active Abandoned
- 2007-10-26 US US11/978,107 patent/US7605252B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,106 patent/US7655789B2/en not_active Expired - Lifetime
- 2007-10-26 US US11/978,070 patent/US7582746B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,097 patent/US7638622B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,120 patent/US20080081904A1/en not_active Abandoned
- 2007-10-29 US US11/978,475 patent/US20080113372A1/en not_active Abandoned
- 2007-10-29 US US11/978,457 patent/US20080113371A1/en not_active Abandoned
- 2007-10-29 US US11/978,455 patent/US7795421B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/978,487 patent/US20080113374A1/en not_active Abandoned
- 2007-10-29 US US11/978,398 patent/US7709629B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/978,518 patent/US7632938B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/978,476 patent/US7635771B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/980,102 patent/US7662950B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/980,263 patent/US7632939B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/980,300 patent/US7592443B2/en not_active Expired - Fee Related
-
2009
- 2009-01-23 US US12/321,749 patent/US7666853B2/en not_active Expired - Fee Related
- 2009-02-02 US US12/322,387 patent/US7589191B2/en not_active Expired - Fee Related
- 2009-05-28 US US12/455,098 patent/US7741470B2/en not_active Expired - Fee Related
- 2009-07-24 US US12/460,876 patent/US20100004141A1/en not_active Abandoned
- 2009-07-28 US US12/462,029 patent/US7745612B2/en not_active Expired - Fee Related
- 2009-08-04 US US12/462,420 patent/US7737267B2/en not_active Expired - Fee Related
- 2009-08-10 US US12/462,820 patent/US8022198B2/en not_active Expired - Fee Related
- 2009-09-03 US US12/584,352 patent/US8222395B2/en not_active Expired - Fee Related
- 2009-09-11 US US12/584,850 patent/US7897754B2/en not_active Expired - Fee Related
- 2009-09-17 US US12/586,167 patent/US7855186B2/en not_active Expired - Fee Related
- 2009-10-29 US US12/589,879 patent/US8039610B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/590,097 patent/US7816512B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/590,252 patent/US7829696B2/en not_active Expired - Fee Related
- 2009-12-03 US US12/592,872 patent/US8304528B2/en active Active
- 2009-12-08 US US12/653,120 patent/US8022199B2/en not_active Expired - Fee Related
- 2009-12-11 US US12/653,402 patent/US7807820B2/en not_active Expired - Fee Related
- 2009-12-23 US US12/655,107 patent/US7833989B2/en not_active Expired - Fee Related
-
2010
- 2010-01-21 US US12/657,448 patent/US8067576B2/en not_active Expired - Lifetime
- 2010-03-01 US US12/660,582 patent/US8247169B2/en not_active Expired - Lifetime
- 2010-04-07 US US12/798,603 patent/US8030476B2/en not_active Expired - Fee Related
- 2010-04-12 US US12/798,802 patent/US7935813B2/en not_active Expired - Fee Related
- 2010-04-13 US US12/798,906 patent/US8236942B2/en not_active Expired - Lifetime
- 2010-04-30 US US12/799,758 patent/US8217162B2/en not_active Expired - Lifetime
- 2010-05-05 US US12/799,975 patent/US20100267587A1/en not_active Abandoned
- 2010-07-12 US US12/804,014 patent/US8071754B2/en not_active Expired - Fee Related
- 2010-08-17 US US12/806,570 patent/US7999097B2/en not_active Expired - Fee Related
- 2010-09-08 US US12/807,526 patent/US8222396B2/en not_active Expired - Fee Related
- 2010-09-20 US US12/924,078 patent/US8268985B2/en not_active Expired - Lifetime
- 2010-10-01 US US12/924,653 patent/US8138329B2/en not_active Expired - Fee Related
- 2010-11-08 US US12/927,144 patent/US8314229B2/en not_active Expired - Fee Related
-
2011
- 2011-07-01 US US13/135,336 patent/US8293887B2/en not_active Expired - Lifetime
- 2011-08-10 US US13/136,780 patent/US8633306B2/en not_active Expired - Fee Related
- 2011-08-11 US US13/136,812 patent/US8426579B2/en not_active Expired - Fee Related
- 2011-08-23 US US13/199,240 patent/US20110319297A1/en not_active Abandoned
- 2011-09-13 US US13/199,946 patent/US20120015850A1/en not_active Abandoned
- 2011-10-27 US US13/317,752 patent/US8232386B2/en not_active Expired - Lifetime
-
2012
- 2012-02-14 US US13/385,320 patent/US8461326B2/en not_active Expired - Fee Related
- 2012-06-06 US US13/489,725 patent/US20120252873A1/en not_active Abandoned
- 2012-06-12 US US13/494,360 patent/US20120258888A1/en not_active Abandoned
- 2012-06-15 US US13/524,015 patent/US8575329B2/en not_active Expired - Fee Related
- 2012-06-28 US US13/536,005 patent/US8445668B2/en not_active Expired - Fee Related
- 2012-07-02 US US13/539,630 patent/US20120270751A1/en not_active Abandoned
- 2012-07-05 US US13/542,332 patent/US20120283311A1/en not_active Abandoned
- 2012-07-18 US US13/551,794 patent/US8658784B2/en not_active Expired - Fee Related
- 2012-09-13 US US13/613,910 patent/US20130023446A1/en not_active Abandoned
- 2012-10-01 US US13/632,519 patent/US20130059760A1/en not_active Abandoned
- 2012-10-09 US US13/647,869 patent/US8658785B1/en not_active Expired - Fee Related
-
2013
- 2013-03-20 US US13/847,544 patent/US8883998B2/en not_active Expired - Fee Related
- 2013-04-22 US US13/867,175 patent/US20130225447A1/en not_active Abandoned
- 2013-12-06 US US14/099,339 patent/US8907077B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150945A1 (en) * | 2000-12-28 | 2002-10-17 | Cell Therapeutics, Inc. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
US20050130181A1 (en) * | 2001-05-18 | 2005-06-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20050239731A1 (en) * | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
US20030105051A1 (en) * | 2001-05-29 | 2003-06-05 | Mcswiggen James | Nucleic acid treatment of diseases or conditions related to levels of HER2 |
US20040054155A1 (en) * | 2002-02-01 | 2004-03-18 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
US20040180357A1 (en) * | 2002-11-01 | 2004-09-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
US20070031844A1 (en) * | 2002-11-14 | 2007-02-08 | Anastasia Khvorova | Functional and hyperfunctional siRNA |
US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
US20050181382A1 (en) * | 2003-06-02 | 2005-08-18 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US20050186586A1 (en) * | 2003-06-02 | 2005-08-25 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10125369B2 (en) | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
US10851377B2 (en) | 2015-08-25 | 2020-12-01 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070260051A1 (en) | siRNA targeting pituitary tumor-transforming 1 (PTTG1) | |
US10774332B2 (en) | Interfering RNA molecules | |
US8841267B2 (en) | Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs | |
JP6425775B2 (en) | Induction of exon skipping in eukaryotic cells | |
US20050176045A1 (en) | SNP discriminatory siRNA | |
JP2006507841A (en) | Functional and ultrafunctional siRNA | |
US20060223777A1 (en) | Highly functional short hairpin RNA | |
EP1389637A1 (en) | Novel forms of interfering RNA molecules | |
WO2011053144A2 (en) | Methods and compositions for dysferlin exon-skipping | |
Martin et al. | A single amino acid substitution in ORF1 dramatically decreases L1 retrotransposition and provides insight into nucleic acid chaperone activity | |
US9206426B2 (en) | Inhibitory RNAs to RNA binding proteins hnRNPA1, hnRNPA2 and PTB and uses thereof | |
WO2005090606A2 (en) | Identification of toxic nucleotide sequences | |
Rakoczy | Antisense DNA technology | |
AU2018200311B2 (en) | Further novel forms of interfering rna molecules | |
Takei et al. | In vivo delivery technique of nucleic acid compounds using atelocollagen: its use in cancer therapeutics targeted at the heparin-binding growth factor midkine | |
US20120110686A1 (en) | Cand45 tRNA-Derived Expression System for Gene Modulation | |
AU2012216354B2 (en) | Further novel forms of interfering RNA molecules | |
Grimpe | Aspects of antisense oligodeoxynucleotide, ribozyme, DNA enzyme and RNAi design | |
Yu et al. | Approaches for Manipulation of Gene Expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DHARMACON, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KHVOROVA, ANASTASIA;REYNOLDS, ANGELA;LEAKE, DEVIN;AND OTHERS;REEL/FRAME:019484/0743;SIGNING DATES FROM 20070416 TO 20070521 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |